<SEC-DOCUMENT>0000318154-25-000005.txt : 20250204
<SEC-HEADER>0000318154-25-000005.hdr.sgml : 20250204
<ACCEPTANCE-DATETIME>20250204160522
ACCESSION NUMBER:		0000318154-25-000005
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20250204
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250204
DATE AS OF CHANGE:		20250204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMGEN INC
		CENTRAL INDEX KEY:			0000318154
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				953540776
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37702
		FILM NUMBER:		25588111

	BUSINESS ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320
		BUSINESS PHONE:		(805)447-1000

	MAIL ADDRESS:	
		STREET 1:		ONE AMGEN CENTER DRIVE
		CITY:			THOUSAND OAKS
		STATE:			CA
		ZIP:			91320

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMGEN
		DATE OF NAME CHANGE:	19870305
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>amgn-20250204.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:66a43e5f-8b4e-44fe-ab55-0db62824ab75,g:f296f254-0b7c-4964-aa80-33e600c2767c,d:2d66918fbeee41578c28c72c18b41bb4-->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:amgn="http://www.amgen.com/20250204" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>amgn-20250204</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-24">0000318154</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-25">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="amgn-20250204.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-04</xbrli:startDate><xbrli:endDate>2025-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-04</xbrli:startDate><xbrli:endDate>2025-02-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000318154</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-04</xbrli:startDate><xbrli:endDate>2025-02-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2d66918fbeee41578c28c72c18b41bb4_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 OR 15(d) of</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Securities Exchange Act of 1934</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported)</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">February&#160;4, 2025</ix:nonNumeric></span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;-</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Amgen Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.919%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37702</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">95-3540776</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">One Amgen Center Drive</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Thousand Oaks</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">91320-1799</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">805</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">447-1000</ix:nonNumeric> </span></div><div style="margin-bottom:1.5pt;text-align:center"><span><br/></span></div><div style="margin-bottom:1.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:32.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.643%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.336%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-17">Common stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-18">AMGN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-20">2.000% Senior Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-21">AMGN26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2). Emerging growth company&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-23">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:1.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:1.5pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><div id="i2d66918fbeee41578c28c72c18b41bb4_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.02 Results of Operations and Financial Condition.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Fourth Quarter and Full Year 2024 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-26">February&#160;4, 2025</ix:nonNumeric>, the Company issued a press release announcing its unaudited results of operations for the three months and year ended December 31, 2024, and its unaudited financial position as of December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 hereto.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In its press release the Company included certain non-U.S. Generally Accepted Accounting Principles (GAAP) financial measures as defined in Regulation G promulgated by the Securities and Exchange Commission. The non-GAAP financial measures included in the press release are non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP operating expenses and sub-components of non-GAAP operating expenses such as non-GAAP cost of sales, non-GAAP research and development (R&amp;D) expenses and non-GAAP selling, general and administrative expenses. Reconciliations for such non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the press release. The Company included Free Cash Flow (FCF), which is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP. The Company also included Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) for the year ended December 31, 2024, calculated by adding interest expense, provision for income taxes, and depreciation and amortization expense to GAAP net income, and debt leverage ratio, calculated as the ratio of GAAP total debt to EBITDA.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that this presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses certain non-GAAP financial measures to enhance an investor&#8217;s overall understanding of the financial performance and prospects for the future of the Company&#8217;s ongoing business activities by facilitating comparisons of results of ongoing business operations among current, past and future periods. The Company believes that FCF provides a further measure of the Company&#8217;s liquidity. Further, the Company believes its debt leverage ratio provides a supplemental operating metric for the full year period as it compares the amount of cash generated by our operations during the year ended December&#160;31, 2024. The Company uses non-GAAP financial measures in connection with its own budgeting and financial planning internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the costs and other items excluded from the most directly comparable GAAP financial measures to calculate non-GAAP financial measures:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Acquisition-related expenses: Acquisition-related charges are primarily associated with assets acquired in connection with business acquisitions, including intangible assets and acquired inventory. Such charges include amortization of developed-product-technology rights, licensing rights, R&amp;D technology rights, marketing-related rights and step-up to fair value of acquired inventory, as well as net impairment charges of in-process R&amp;D assets. Net charges for purchased intangible assets are significantly impacted by the timing and magnitude of the Company&#8217;s acquisitions and potential product approvals as they relate to in-process R&amp;D projects acquired. Accordingly, these net charges may vary in amount from period to period. The Company excludes these net charges for purposes of calculating the non-GAAP financial measures presented to facilitate a more meaningful evaluation of the Company&#8217;s current operating performance and comparisons to past operating performance. The Company believes that excluding noncash net charges related to those intangible assets and inventory acquired in business acquisitions treats those assets as if the Company had developed them internally in the past and, thus, provides a supplemental measure of profitability in which these acquired assets are treated in a comparable manner to the Company's internally developed or produced assets.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Net charges pursuant to the Company&#8217;s restructuring and cost savings initiatives: Costs from restructuring and cost savings initiatives are primarily related to facilities charges, including asset impairments and accelerated depreciation, and severance and benefits for employees terminated pursuant to our transformation and process improvement efforts. Costs from such initiatives are inconsistent in amount and are significantly impacted by the timing and nature of these events. Therefore, although the Company may incur these types of expenses in the future, it believes that eliminating these charges for purposes of calculating the non-GAAP financial measures provides a supplemental evaluation of the Company&#8217;s current operating performance and facilitates comparisons to past operating performance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Other items: The Company adjusts GAAP financial results for certain income and expenses (or gains and losses). These adjustments include: (1) gains and losses on our investments in equity securities; (2) certain items associated with judgments and/or settlements for legal proceedings discussed in our filings; and (3) (i) interest expense and income on senior notes issued in March 2023 and (ii) debt issuance costs and other fees related to our bridge credit agreement and term loan credit agreement, incurred prior to the closing of our acquisition of Horizon Therapeutics plc. The Company excludes these items for the purpose of calculating the non-GAAP financial measures presented because the Company believes these items are outside the ordinary course of business. The Company believes eliminating these items provides a supplemental evaluation of the Company&#8217;s current operating performance and facilitates comparisons to past operating performance.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">The tax effect of the adjustments between GAAP and non-GAAP results take into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Generally, the tax impact of adjustments, including the amortization of intangible assets and acquired inventory, gains and losses on our investments in equity securities and expenses related to restructuring and cost savings initiatives, depends on whether the amounts are deductible in the respective tax jurisdictions and the applicable tax rate(s) in those jurisdictions.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The press release also contains a discussion of the additional purposes for which the Company&#8217;s management uses these non-GAAP financial measures.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This information and the information contained in the press release shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report is not incorporated by reference into any filings of the Company made under the Securities Act of 1933, as amended, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing unless specifically stated so therein.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><div id="i2d66918fbeee41578c28c72c18b41bb4_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.01 Financial Statements and Exhibits.</span></div><div style="margin-bottom:6pt;margin-top:4.4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-bottom:6pt;margin-top:4.4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:7.602%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:89.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="amgn-20241231earningsrelea.htm">Press Release dated February 4, 2025.</a></span></div></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div><div id="i2d66918fbeee41578c28c72c18b41bb4_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9.9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.577%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.703%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMGEN INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-27">February 4, 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Peter H. Griffith</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter H. Griffith</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-indent:22.5pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>amgn-20241231earningsrelea.htm
<DESCRIPTION>EARNINGS RELEASE
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="icaa4bd57b13d49fe85974fadacdcc0a8_1"></div><div style="min-height:67.5pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:32.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.864%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><img alt="amgenlogoa.jpg" src="amgenlogoa.jpg" style="height:54px;margin-bottom:5pt;vertical-align:text-bottom;width:175px"></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:18pt;font-style:italic;font-weight:700;line-height:100%">News Release</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:100%">One Amgen Center Drive<br>Thousand Oaks, CA 91320-1799<br>Telephone 805-447-1000<br>www.amgen.com</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div id="icaa4bd57b13d49fe85974fadacdcc0a8_4"></div><div style="text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:16pt;font-weight:700;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">THOUSAND OAKS, Calif. (Feb. 4, 2025) - Amgen (NASDAQ&#58;AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.</font></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">&#8220;Robust growth in sales and earnings throughout 2024 reflects the momentum of our business. With strong performance globally, we are investing heavily in our rapidly advancing pipeline to deliver innovative therapies across our four therapeutic areas,&#34; said Robert A. Bradway, chairman and chief executive officer.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Key results include&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">For the fourth quarter, total revenues increased 11% to $9.1 billion in comparison to the fourth quarter of 2023.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Produ</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ct sales grew </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11%</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, primarily driven by 14% volume growth. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Excluding sales from our Horizon Therapeutics (Horizon) acquisition, product sales grew 10%, driven by volume growth of 15%.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Ten products delivered at least double-digit sales growth in the fourth quarter, including Repatha</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (evolocumab), BLINCYTO</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (blinatumomab), TEZSPIRE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (tezepelumab-ekko), EVENITY</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (romosozumab-aqqg), and TAVNEOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(avacopan).</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Our performance included $1.2 billion of sales from our rare disease products, driven by several first-in-class, early-in-lifecycle medicines, including TEPEZZA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (teprotumumab-trbw), KRYSTEXXA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (pegloticase), UPLIZNA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (inebilizumab-cdon), and TAVNEOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">For the full year, total revenues increased 19% to $33.4 billion in comparison to the full year of 2023. </font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Produ</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ct sales grew </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19%</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, primarily driven by 23% volume growth, partially offset by 2% lower net selling price. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Excluding sales from our Horizon acquisition, product sales grew 7%, driven by volume growth of 11%.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Ten products delivered at least double-digit sales growth for the full year, including Repatha</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, TEZSPIRE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, EVENITY</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, BLINCYTO</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and TAVNEOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">21 products achieved record sales for the full year.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">GAAP earnings per share (EPS) decreased 18% from $1.42 to $1.16 for the fourth quarter, primarily driven by mark-to-market losses on our equity investments, partially offset by higher revenues. For the full year, GAAP EPS decreased 39% from $12.49 to $7.56, primarily </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 2</font></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">driven by higher operating expenses, including amortization expense from Horizon acquisition-related assets and incremental operating expenses from Horizon, and overall mark-to-market losses on our equity investments in 2024, partially offset by higher revenues.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">For the fourth quarter, GAAP operating income increased from $1.3 billion to $2.3 billion, and GAAP operating margin increased 10.3 percentage points to 26.5%. For the full year, GAAP operating income decreased from $7.9 billion to $7.3 billion, and GAAP operating margin decreased 6.6 percentage points to 22.7%.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Non-GAAP EPS increased 13% from $4.71 to $5.31 for the fourth quarter, driven by higher revenues, partially offset by higher operating expenses. For the full year, non-GAAP EPS increased 6% from $18.65 to $19.84, driven by higher revenues, partially offset by higher operating expenses, including incremental operating expenses from Horizon, and higher interest expense.</font></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">For the fourth quarter, non-GAAP operating income increased from $3.7 billion to $4.0 billion, and non-GAAP operating margin decreased 0.4 percentage points to 46.3%. For the full year, non-GAAP operating income increased from $13.4 billion to $15.0 billion, and non-GAAP operating margin decreased 2.9 percentage points to 46.9%.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The Company generated $10.4 billion of free cash flow for the full year versus $7.4 billion in 2023, driven by business performance and timing of working capital items, primarily collections, partially offset by higher net interest expense.</font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">References in this release to &#8220;non-GAAP&#8221; measures, measures presented &#8220;on a non-GAAP basis,&#8221; &#8220;free cash flow&#8221; (computed by subtracting capital expenditures from operating cash flow), &#8220;EBITDA, or earnings before interest, taxes, depreciation and amortization&#8221; (computed by adding interest expense, provision for income taxes, and depreciation and amortization expense to GAAP net income) and &#8220;debt leverage ratio&#8221; (calculated as the ratio of GAAP total debt to EBITDA) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. Refer to Non-GAAP Financial Measures below for further discussion.</font></div><div style="text-align:justify"><font><br></font></div><div id="icaa4bd57b13d49fe85974fadacdcc0a8_7"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Sales Performance </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">General Medicine</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Repatha</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (evolocumab)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sales increased 45% year-over-year to $606 million in the fourth quarter, primarily driven by volume growth. Full year sales increased 36%, primarily driven by 43% volume growth, partially offset by 10% lower net selling price. For 2025, we expect lower declines in net selling price.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">EVENITY</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (romosozumab-aqqg) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 36% year-over-year to $431 million in the fourth quarter and 35% for the full year, driven by volume growth. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Prolia</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (denosumab)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sales increased 5% year-over-year to $1.2 billion in the fourth quarter and 8% for the full year, driven by volume growth. For 2025, we expect sales erosion driven by biosimilar competition.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 3</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Rare Disease</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Except for TAVNEOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the products listed below were added through the acquisition of Horizon on Oct. 6, 2023. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">TEPEZZA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(teprotumumab-trbw)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> generated $460 million of sales in the fourth quarter and $1.9 billion for the full year. TEPEZZA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">is the first and only approved treatment for thyroid eye disease (TED) in the U.S. and Japan. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">KRYSTEXXA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (pegloticase)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> generated $346 million of sales in the fourth quarter and $1.2 billion for the full year. KRYSTEXXA is the first and only FDA-approved treatment for chronic refractory gout.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">UPLIZNA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (inebilizumab-cdon)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> generated $101 million of sales in the fourth quarter and $379 million for the full year. UPLIZNA is used to treat adults with neuromyelitis optica spectrum disorder (NMOSD).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">TAVNEOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (avacopan)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> generated $81 million of sales in the fourth quarter. Sales increased 84% year-over-year in the fourth quarter and 111% for the full year, primarily driven by volume growth. TAVNEOS is a first-in-class treatment for severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis). </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Ultra-Rare products</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, which consist of </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RAVICTI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (glycerol phenylbutyrate)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PROCYSBI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (cysteamine bitartrate)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ACTIMMUNE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (interferon gamma-1b)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">QUINSAIR</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (levofloxacin)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BUPHENYL</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (sodium phenylbutyrate)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">generated $214 million of sales in the fourth quarter and $758 million for the full year. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Inflammation</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">TEZSPIRE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (tezepelumab-ekko)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sales increased 67% year-over-year to $296 million in the fourth quarter and 71% for the full year, primarily driven by volume growth.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Otezla</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (apremilast) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales decreased 1% year-over-year to $624 million in the fourth quarter, driven by 7% lower net selling price, partially offset by 5% volume growth. Sales decreased 3% for the full year, primarily driven by 8% lower net selling price, partially offset by 3% volume growth.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Enbrel</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (etanercept) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales were flat year-over-year at $1.0 billion in the fourth quarter as 7% favorable changes to estimated sales deductions were offset by lower net selling price. Full year sales decreased 10%, driven by lower net selling price. For 2025, we expect continued declining net selling price and relatively flat volumes.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We expect Otezla and Enbrel to follow the historical pattern of lower sales in the first quarter relative to subsequent quarters due to the impact of benefit plan changes, insurance reverification and increased co-pay expenses as U.S. patients work through deductibles.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">AMJEVITA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#47;AMGEVITA&#8482; (adalimumab) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 84% year-over-year to $294 million in the fourth quarter and 22% for the full year, driven by volume growth, partially offset by lower net selling price.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 4</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Oncology</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">BLINCYTO</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (blinatumomab)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sales increased 58% year-over-year to $381 million in the fourth quarter and 41% for the full year, primarily driven by volume growth. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Vectibix</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (panitumumab)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sales decreased 2% year-over-year to $246 million in the fourth quarter, driven by 5% unfavorable foreign exchange impact and 4% lower volume, partially offset by higher net selling price. Sales increased 6% for the full year, driven by 8% higher net selling price and 4% volume growth, partially offset by unfavorable foreign exchange impact.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">KYPROLIS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (carfilzomib)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sales increased 6% year-over-year to $372 million in the fourth quarter and 7% for the full year, driven by volume growth outside the U.S.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">LUMAKRAS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#47;LUMYKRAS&#8482; (sotorasib) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 10% year-over-year to $85 million in the fourth quarter, primarily driven by volume growth. Sales increased 25% for the full year, driven by volume growth and favorable changes to estimated sales deductions.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">XGEVA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (denosumab) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales increased 6% year-over-year to $561 million in the fourth quarter, driven by volume growth. Sales increased 5% for the full year, driven by higher net selling price. For 2025, we expect sales erosion driven by biosimilar competition.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Nplate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (romiplostim)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> sales decreased 13% year-over-year to $337 million in the fourth quarter. Excluding a fourth quarter 2023 U.S. government order of $62 million, Nplate sales grew 4% year-over-year in the fourth quarter, driven by volume growth. Full year sales decreased 1%. U.S. government orders were $128 million in 2024 compared to $286 million in 2023. Excluding these U.S. government orders, Nplate sales grew 12% year-over-year for the full year, driven by 8% volume growth and 6% higher net selling price.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">IMDELLTRA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (tarlatamab-dlle)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> generated $67 million of sales in the fourth quarter. Sales increased 86% quarter-over-quarter, driven by volume growth and inventory levels. IMDELLTRA is the first and only FDA-approved bispecific T-cell engager (BiTE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) therapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">MVASI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (bevacizumab-awwb) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">sales decreased 8% year-over-year to $173 million in the fourth quarter and 9% for the full year.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Established Products</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Our established products, which consist of </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EPOGEN</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (epoetin alfa)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Aranesp</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (darbepoetin alfa)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Parsabiv</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (etelcalcetide)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">and</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> Neulasta</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> (pegfilgrastim)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, generated $500 million of sales in the fourth quarter. Sales decreased 29% year-over-year for the fourth quarter, driven by volume declines, unfavorable changes to estimated sales deductions and lower net selling price. Sales decreased 19% for the full year, driven by volume declines, lower net selling price and unfavorable changes to estimated sales deductions. </font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="icaa4bd57b13d49fe85974fadacdcc0a8_10"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 5</font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Sales Detail by Product and Geographic Region</font></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.673%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Millions, except percentages</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q4 &#8217;24</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q4 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,107&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEPEZZA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KRYSTEXXA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UPLIZNA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAVNEOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ultra-Rare products</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enbrel</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMJEVITA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;AMGEVITA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;LUMYKRAS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">561&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMDELLTRA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPOGEN</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,509&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,207&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,716&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,833&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</font></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A &#61; not applicable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="33" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Horizon-acquired products, and the Ultra-Rare products consist of RAVICTI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, PROCYSBI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, ACTIMMUNE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, QUINSAIR</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and BUPHENYL</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Consists of (i) Aimovig</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVSOLA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, RIABNI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PAVBLU</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, NEUPOGEN</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, WEZLANA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;WEZENLA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, BEKEMV</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, IMLYGIC</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corlanor</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and Sensipar</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;Mimpara</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, where Biosimilars total $218 million in Q4 &#8217;24 and $135 million in Q4 &#8217;23&#59; and (ii) Horizon-acquired products including RAYOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PENNSAID</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and DUEXIS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="margin-bottom:1pt;text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 6</font></div></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Millions, except percentages</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FY &#8217;24</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FY &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repatha</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,139&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,083&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,222&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,635&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EVENITY</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,563&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prolia</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,048&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEPEZZA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,851&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KRYSTEXXA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UPLIZNA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAVNEOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ultra-Rare products</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEZSPIRE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Otezla</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,699&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enbrel</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,288&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,316&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,697&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMJEVITA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;AMGEVITA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vectibix</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,045&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">984&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LUMAKRAS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;LUMYKRAS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,507&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,225&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nplate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMDELLTRA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVASI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPOGEN</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aranesp</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,362&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parsabiv</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neulasta</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">848&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49%)</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other products</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,115&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,301&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,725&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,026&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,910&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</font></td></tr><tr style="height:6pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* Change in excess of 100%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A &#61; not applicable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="33" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Horizon-acquired products, and the Ultra-Rare products consist of RAVICTI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, PROCYSBI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, ACTIMMUNE</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, BUPHENYL</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUINSAIR</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Consists of (i) Aimovig</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KANJINTI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RIABNI</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVSOLA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, NEUPOGEN</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, Corlanor</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:1.41pt;vertical-align:baseline">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> IMLYGIC</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BEKEMV</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, PAVBLU</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, WEZLANA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;WEZENLA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and Sensipar</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;Mimpara</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, where Biosimilars total $725 million in FY &#8217;24 and $490 million in FY &#8217;23&#59; and (ii) Horizon-acquired products including RAYOS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PENNSAID</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and DUEXIS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 7</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating Expense, Operating Margin and Tax Rate Analysis</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On a GAAP basis&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.4pt">Total Operating Expenses </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">decreased 2% year-over-year for the fourth quarter and increased 29% for the full year. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Sales</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as a percentage of product sales decreased 4.0 percentage points for the fourth quarter primarily driven by lower amortization expense from the fair value step-up of inventory acquired from Horizon, partially offset by changes in our sales mix, and higher profit share and royalty expense. For the full year, cost of sales as a percentage of product sales increased 8.7 percentage points driven by higher amortization expense from Horizon acquisition-related assets and, to a lesser extent, higher profit share and royalty expense, partially offset by the Puerto Rico excise tax. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Research &#38; Development (R&#38;D) </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expenses increased 12% for the fourth quarter driven by higher spend in later-stage clinical programs, partially offset by lower research and early pipeline spend. R&#38;D expenses increased 25% for the full year driven by higher spend in later-stage clinical programs and marketed products support, including spend from Horizon-acquired programs. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selling, General &#38; Administrative (SG&#38;A)</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> expenses decreased 17% for the fourth quarter primarily driven by lower Horizon acquisition-related expenses. SG&#38;A expenses increased 15% for the full year primarily driven by expenses from the acquired Horizon business and other commercial expenses, partially offset by lower Horizon acquisition-related expenses incurred in 2024. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> operating expenses for the full year primarily consisted of impairment charges associated with in-process R&#38;D (IPR&#38;D) intangible assets related to our Teneobio, Inc. acquisition in 2021 and expenses related to cost-savings initiatives incurred in 2024.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Operating Margin</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as a percentage of product sales increased 10.3 percentage points to 26.5% for the fourth quarter and decreased 6.6 percentage points to 22.7% for the full year.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Tax Rate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> increased 9.8 percentage points in the fourth quarter and decreased 3.2 percentage points for the full year. The fourth quarter tax rate increase was related to deferred tax adjustments associated with the U.S. minimum tax on the earnings of our foreign subsidiaries and prior year favorable items, partially offset by the change in earnings mix as a result of the fourth quarter 2024 unrealized losses on our strategic equity investments (primarily BeiGene). The full year tax rate decrease was due to the change in earnings mix, including the net unrealized impacts of our strategic equity investments (primarily BeiGene), partially offset by the deferred tax adjustments associated with the U.S. minimum tax on the earnings of our foreign subsidiaries.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 8</font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On a non-GAAP basis&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.4pt">Total Operating Expenses </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">increased 11% year-over-year for the fourth quarter and increased 24% for the full year. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Sales</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as a percentage of product sales increased 1.3 percentage points for the fourth quarter driven by changes in our sales mix, and higher profit share and royalty expense. Cost of sales as a percentage of product sales increased 0.9 percentage points for the full year driven by higher profit share and royalty expense, partially offset by the Puerto Rico excise tax. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">R&#38;D </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expenses increased 14% for the fourth quarter driven by higher spend in later-stage clinical programs, partially offset by lower spend in research and early pipeline. R&#38;D expenses increased 25% for the full year driven by higher spend in later-stage clinical programs and marketed products support, including spend from Horizon-acquired programs. </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SG&#38;A</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> expenses increased 3% for the fourth quarter driven by higher general and administrative expenses. SG&#38;A expenses increased 23% for the full year primarily driven by expenses from the acquired Horizon business and other marketed product expenses.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.4pt">Operating Margin</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> as a percentage of product sales decreased 0.4 percentage points to 46.3% for the fourth quarter and decreased 2.9 percentage points to 46.9% for the full year.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Tax Rate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> decreased 1.1 percentage points for the fourth quarter and decreased 2.0 percentage points for the full year. The fourth quarter tax rate decrease was primarily due to the change in earnings mix and net favorable items as compared to the prior year. The full year tax rate decrease was primarily due to the change in earnings mix as a result of the inclusion of the Horizon business and net favorable items as compared to the prior year.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 9</font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Millions, except percentages</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q4 &#8217;24</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q4 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q4 &#8217;24</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q4 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Sales</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,112&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,112&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0) pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 pts.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research &#38; Development</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 pts.</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, General &#38; Administrative</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17%)</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5) pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6) pts.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Operating Expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,775</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,925</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2%)</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,053</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,536</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11%</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Margin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">operating income as % of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4) pts.</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax Rate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.8</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.0</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.8 pts. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.9</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.1) pts.</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">pts&#58; percentage points</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* change in excess of 100%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A &#61; not applicable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Millions, except percentages</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FY '24</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FY '23</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FY '24</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FY '23</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Sales</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,858&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,451&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,736&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,573&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 pts.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research &#38; Development</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,964&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,784&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,878&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,700&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 pts.</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, General &#38; Administrative</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,096&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,179&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,782&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,518&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">% of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8) pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7 pts.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72%)</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Operating Expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,166</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,293</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29%</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,396</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,791</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24%</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Margin</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">operating income as % of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6) pts.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9) pts.</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax Rate</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.3</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.5</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.2) pts. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.5</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.5</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.0) pts.</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">pts&#58; percentage points</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N&#47;A &#61; not applicable</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Flow and Balance Sheet</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The Company generated a record $4.4 billion of free cash flow in the fourth quarter of 2024 versus $0.3 billion in the fourth quarter of 2023, driven by timing of tax payments, timing of working capital, primarily collections, lower transaction expenses compared to the fourth quarter of 2023, which included significant costs tied to the closing of the Horizon acquisition, and business performance. The Company generated $10.4 billion of free cash flow for the full year 2024 versus $7.4 billion in 2023.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 10</font></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">The Company&#8217;s fourth quarter 2024 dividend of $2.25 per share was declared on October&#160;25, 2024, and was paid on December&#160;9, 2024, to all stockholders of record as of November&#160;18, 2024, representing a 6% increase from the same period in 2023.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">During the fourth quarter, there were no repayments or extinguishments of debt. For the full year 2024, the Company reduced principal debt outstanding by $4.5&#160;billion.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">For the fourth quarter and full year, the Company repurchased 0.7 million shares of common stock at a total cost of $200 million.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.4pt">Cash and investments totaled $12.0 billion and debt outstanding totaled $60.1 billion as of December 31, 2024. Debt leverage was approximately 4.5 times EBITDA as of December 31, 2024.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.509%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Billions, except shares</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q4 &#8217;24</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q4 &#8217;23</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FY '24</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FY '23</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YOY &#916;</font></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating Cash Flow</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital Expenditures</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free Cash Flow</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends Paid</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share Repurchases</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average Diluted Shares (millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note&#58; Numbers may not add due to rounding</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.292%"><tr><td style="width:1.0%"></td><td style="width:54.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.686%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$Billions</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12&#47;31&#47;24</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12&#47;31&#47;23</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YTD &#916;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Investments</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt Outstanding</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</font></td><td style="border-right:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note&#58; Numbers may not add due to rounding</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2025 Guidance</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the full year 2025, the Company expects&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Total revenues</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of $34.3&#160;billion to $35.7&#160;billion.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">On a </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP basis, EPS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of $10.89 to $12.14, and a </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">tax rate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of 11.0% to 12.5%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">On a </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">non-GAAP basis, EPS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of $20.00 to $21.20, and a </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">tax rate</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in the range of 15.0% to 16.0%.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Capital expenditures</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> to be approximately $2.3&#160;billion.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:11.34pt">Share repurchases</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> not to exceed $500&#160;million.</font></div><div style="text-align:justify"><font><br></font></div><div id="icaa4bd57b13d49fe85974fadacdcc0a8_13"></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fourth Quarter Product and Pipeline Update</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company provided the following updates on selected product and pipeline programs&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">General Medicine</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">MariTide (maridebart cafraglutide, AMG 133)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">MariTide is a differentiated peptide-antibody conjugate that activates the glucagon like peptide 1 (GLP-1) receptor and antagonizes gastric inhibitory polypeptide receptor (GIPR).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In November 2024, data were presented from Part 1 of a Phase 2 chronic weight management study in adults who are living with overweight or obesity, with or without </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 11</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Type 2 diabetes mellitus. MariTide demonstrated robust weight loss at 52 weeks without a weight loss plateau, significant improvements in cardiometabolic parameters, and is the first obesity treatment with monthly or less frequent dosing to demonstrate safe and effective weight loss in a Phase 2 study.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Part 2 of the Phase 2 chronic weight management study is ongoing in adults who are living with overweight or obesity, with or without Type 2 diabetes mellitus. Data readout is anticipated in H2 2025. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2 study investigating MariTide for the treatment of Type 2 diabetes mellitus is enrolling adults living with and without obesity. Data readout is anticipated in H2 2025.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Planning for MARITIME, a broad Phase 3 program across multiple indications remains on track with the first studies expected to begin in H1 2025.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">AMG 513</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1 study of AMG 513 in people living with obesity was placed on clinical hold by the U.S. Food and Drug Administration (FDA). Discussions are underway on a path forward to reopen the study.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Olpasiran (AMG 890) </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Olpasiran is a potentially best-in-class small interfering ribonucleic acid (siRNA) molecule that reduces lipoprotein(a) (Lp(a)) synthesis in the liver. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The OCEAN(a)-Outcomes trial, a Phase 3 cardiovascular (CV) outcomes study, is ongoing in patients with atherosclerotic CV disease and elevated Lp(a).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 3 CV outcomes study in patients with elevated Lp(a) and at high risk for a CV event is expected to be initiated in H2 2025 &#47; H1 2026.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Repatha</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">VESALIUS-CV, a Phase 3 CV outcomes study of Repatha, is ongoing in patients at high CV risk without prior myocardial infarction or stroke. Data readout is event driven and anticipated in H2 2025.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">EVOLVE-MI, a Phase 4 study of Repatha administered within 10 days of an acute myocardial infarction to reduce the risk of CV events, is ongoing. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Rare Disease</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TAVNEOS </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 3, open-label study of TAVNEOS in combination with rituximab or a cyclophosphamide-containing regimen is enrolling patients from 6 years to &#60; 18 years of age with active ANCA-associated vasculitis (Granulomatosis with Polyangiitis (GPA) &#47; Microscopic Polyangiitis (MPA)).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TEPEZZA</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Regulatory review is underway in multiple additional geographies including with the European Medicines Agency (EMA) where approval is anticipated in H2 2025. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 3 study of TEPEZZA in Japan is enrolling patients with chronic or low clinical activity score TED.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 3 study evaluating the subcutaneous route of administration of teprotumumab is enrolling patients with TED.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 12</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">KRYSTEXXA</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Data were presented in November 2024 from the AGILE study evaluating the safety, tolerability and efficacy of KRYSTEXXA administered with a shorter infusion duration in patients with uncontrolled gout receiving methotrexate as co-administration&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Safety and efficacy data from the 60-minute infusion duration cohort of the AGILE trial are similar to the MIRROR randomized clinical trial and current administration of KRYSTEXXA with methotrexate over at least 120 minutes.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">U.S. Regulatory filing for AGILE is underway.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UPLIZNA </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In January 2025, the FDA granted UPLIZNA Orphan Drug Designation for the treatment of generalized myasthenia gravis (gMG) based upon data from the Phase 3 MINT study. Regulatory filing activities are underway with submission anticipated to be complete in H1 2025.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In November 2024, data were presented and simultaneously published in the </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> from the Phase 3 MITIGATE study evaluating UPLIZNA compared to placebo in patients with immunoglobin G4-related disease (IgG4-RD). In this study, UPLIZNA demonstrated a statistically significant 87% reduction in IgG4-RD flares, this primary endpoint and all key secondary endpoints were met. The safety results in the placebo-controlled period were consistent with the established safety profile of UPLIZNA. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The FDA accepted the regulatory submission for the Phase 3 MITIGATE study under priority review with a Prescription Drug User Fee Act (PDUFA) action date of April 3, 2025.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Dazodalibep</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Dazodalibep is a fusion protein that inhibits CD40L. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Two Phase 3 studies of dazodalibep in Sj&#246;gren&#8217;s disease are enrolling patients. The first study is in patients with moderate-to-severe systemic disease activity, and the second study is in patients with moderate-to-severe symptomatic burden and low systemic disease activity.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Daxdilimab</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Daxdilimab is a fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2 study of daxdilimab is ongoing in patients with moderate-to-severe active primary discoid lupus erythematosus refractory to standard of care.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2 study of daxdilimab is ongoing in patients with dermatomyositis and antisynthetase inflammatory myositis.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Fipaxalparant</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Fipaxalparant is a lysophosphatidic acid receptor 1 (LPAR1) antagonist.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2 study of fipaxalparant in patients with diffuse cutaneous systemic sclerosis is complete. The study did not meet the primary or secondary endpoints. Further development of fipaxalparant in this indication will be discontinued. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Inflammation</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">TEZSPIRE</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The Company is planning to initiate Phase 3 studies in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) and a BEC &#8805; 150 cells&#47;&#181;l. Study initiation is anticipated in H1 2025. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In December, the Company announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps&#58;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 13</font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Patients treated with TEZSPIRE had a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">The safety profile and tolerability of TEZSPIRE in the trial were consistent with the known profile of the medicine.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Regulatory submission is anticipated in H1 2025.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 3 study of TEZSPIRE is enrolling patients with eosinophilic esophagitis.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In severe asthma, the WAYFINDER Phase 3b study is complete and the PASSAGE Phase 4 real-world effectiveness study is ongoing. The SUNRISE Phase 3 study will be discontinued due to limited enrollment.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Rocatinlimab (AMG 451&#47;KHK4083) </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Rocatinlimab is a first-in-class T-cell rebalancing monoclonal antibody targeting the OX40 receptor.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The eight study ROCKET Phase 3 program evaluating rocatinlimab in patients with moderate-to-severe atopic dermatitis (AD) has enrolled over 3300 patients. Enrollment is now complete in seven studies. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Key milestones from the ROCKET Phase 3 program&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">ROCKET SHUTTLE is a 24-week study evaluating rocatinlimab in combination with topical corticosteroids and&#47;or topical calcineurin inhibitors in adult patients with moderate-to-severe AD. Data readout is anticipated in H1 2025.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">ROCKET IGNITE is a 24-week study evaluating rocatinlimab monotherapy in adult patients with moderate-to-severe AD. Data readout is anticipated in H1 2025.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">ROCKET ASCEND is a study evaluating rocatinlimab maintenance therapy in adult and adolescent patients with moderate-to-severe AD. Data readout is anticipated in H2 2025.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">ROCKET ASTRO is a 52-week study evaluating rocatinlimab in adolescent patients with moderate-to-severe AD. Data readout is anticipated in H2 2025. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2 study of rocatinlimab is enrolling patients with moderate-to-severe asthma.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 3 study of rocatinlimab is enrolling patients with prurigo nodularis.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Otezla </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In November 2024, we made six data presentations at the American College of Rheumatology (ACR). Notable highlights include&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">Otezla reduces axial inflammation in patients with psoriatic arthritis (PsA) as assessed by CANDEN Magnetic Resonance Imaging Scoring, results From the Phase 4 MOSAIC study.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">FOREMOST oligoarticular PsA data presentations (4 posters), including 48-week data and data at 16 weeks showing that Otezla was associated with fewer patients progressing from &#60; 4 to &#62; 4 active joints when compared to placebo suggesting that Otezla reduced the progression from oligoarticular to polyarticular PsA. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Blinatumomab</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Blinatumomab is a BiTE molecule targeting CD19.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2 study of blinatumomab in autoimmune disease was initiated in patients with systemic lupus erythematosus (SLE).</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Inebilizumab</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Inebilizumab is a monoclonal antibody targeting CD19.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2 study of inebilizumab in autoimmune disease was initiated in patients with SLE.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 14</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Ordesekimab (AMG 714&#47;PRV-015)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Ordesekimab is a monoclonal antibody that binds interleukin-15.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2b study of ordesekimab, conducted by Provention Bio, a Sanofi Company, in patients with nonresponsive celiac disease was completed as planned and did not meet primary or secondary endpoints. No safety concerns were noted.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">AMG 104 (AZD8630)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">AMG 104 is an inhaled anti-thymic stromal lymphopoietin (TSLP) fragment antigen-binding (Fab).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2 study is enrolling patients with asthma. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Oncology</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">BLINCYTO</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In December 2024, data from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group, were presented and simultaneously published in the </font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. These data demonstrated that BLINCYTO added to chemotherapy significantly improves disease-free survival in newly diagnosed pediatric patients with National Cancer Institute standard risk B-cell precursor acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Golden Gate, a Phase 3 study of BLINCYTO alternating with low-intensity chemotherapy, is enrolling older adult patients with newly diagnosed Philadelphia chromosome (Ph)-negative B-ALL.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1&#47;2 study of subcutaneous blinatumomab is ongoing in the dose-expansion and optimization phase in adult patients with relapsed or refractory Ph-negative B-ALL. The Company is planning to advance blinatumomab subcutaneous administration to a potentially registration-enabling Phase 2 portion of this study with initiation in H2 2025. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">IMDELLTRA</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">IMDELLTRA is a first-in-class delta-like ligand 3 (DLL3) targeting BiTE molecule.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In 2024, IMDELLTRA received accelerated approval in the U.S. for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. Marketing authorizations have subsequently been granted in Japan and in additional countries, including Canada, Brazil, Israel and Great Britain.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The Company is advancing a comprehensive, global clinical development program across extensive-stage and limited-stage small cell lung cancer (SCLC)&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">DeLLphi-304, a Phase 3 study of IMDELLTRA in second-line ES-SCLC, is ongoing. Data readout is anticipated in H1 2025.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">DeLLphi-305, a Phase 3 study of IMDELLTRA and durvalumab is enrolling patients with first-line ES-SCLC in the maintenance setting.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">DeLLphi-306, a Phase 3 study of IMDELLTRA following concurrent chemoradiation therapy, is enrolling patients with limited-stage SCLC.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">DeLLphi-308, a Phase 1b study evaluating subcutaneous tarlatamab, is enrolling patients with second line or later ES-SCLC.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">DeLLphi-309, a Phase 2 study evaluating alternative intravenous dosing regimens in second-line ES-SCLC, was initiated. </font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.25pt">DeLLphi-303, a Phase 1b study of IMDELLTRA in combination with a programmed cell death protein ligand-1 (PD-L1) inhibitor, carboplatin and etoposide or separately in combination with PD-L1 alone, is ongoing in patients with first-line ES-SCLC.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 15</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Xaluritamig (AMG 509)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Xaluritamig is a first-in-class bispecific T-cell engager targeting six-transmembrane epithelial antigen of prostate 1 (STEAP1). </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 3 study of xaluritamig is enrolling patients with metastatic castrate resistant prostate cancer (mCRPC) who have previously been treated with taxane-based chemotherapy.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1 monotherapy dose-expansion study of xaluritamig is enrolling mCRPC patients who have not yet received taxane-based chemotherapy and to enroll patients in a fully outpatient treatment setting to further improve administration convenience.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1 combination of xaluritamig with enzalutamide or abiraterone is enrolling patients with mCRPC in dose-escalation and dose-expansion respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1b study evaluating neoadjuvant xaluritamig therapy prior to radical prostatectomy is enrolling patients with newly diagnosed localized intermediate or high&#8208;risk prostate cancer. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1b study of xaluritamig is enrolling patients with high-risk biochemically recurrent prostate cancer after definitive therapy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">AMG 193</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">AMG 193 is a first-in-class small molecule methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 2 study evaluating the efficacy, safety, tolerability and pharmacokinetics of AMG 193 is enrolling patients with methylthioadenosine phosphorylase (MTAP)-null previously treated advanced non-small cell lung cancer (NSCLC).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1&#47;1b&#47;2 study of AMG 193 is enrolling patients with advanced MTAP-null solid tumors in the dose-expansion portion of the study.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1b study of AMG 193 alone or in combination with other therapies is enrolling patients with advanced MTAP-null thoracic malignancies.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1b study of AMG 193 in combination with other therapies is enrolling patients with advanced MTAP-null gastrointestinal, biliary tract, and pancreatic cancers.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A Phase 1&#47;2 study of AMG 193 in combination with IDE397, an investigational methionine adenosyltransferase 2A (MAT2A) inhibitor, is enrolling patients with advanced MTAP-null solid tumors.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Bemarituzumab</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Bemarituzumab is a first-in-class fibroblast growth factor receptor 2b (FGFR2b) targeting monoclonal antibody. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">FORTITUDE-101, a Phase 3 study of bemarituzumab plus chemotherapy, is ongoing in patients with first-line gastric cancer. Data readout is anticipated in H1 2025. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">FORTITUDE-102, a Phase 1b&#47;3 study of bemarituzumab plus chemotherapy and nivolumab is ongoing in patients with first-line gastric cancer. Phase 3 data readout is anticipated in H2 2025. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">FORTITUDE-103, a Phase 1b&#47;2 study of bemarituzumab plus oral chemotherapy regimens with or without nivolumab, is enrolling patients with first-line gastric cancer.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">FORTITUDE-301, a Phase 1b&#47;2 basket study of bemarituzumab monotherapy, is ongoing in patients with solid tumors with FGFR2b overexpression.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">LUMAKRAS&#47;LUMYKRAS </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">In January 2025, the FDA approved LUMAKRAS in combination with Vectibix as a targeted, biomarker-driven combination therapy for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 16</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">approved test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">CodeBreaK 301, a Phase 3 study of LUMAKRAS in combination with Vectibix and FOLFIRI, is enrolling patients with first-line KRAS G12C&#8211;mutated CRC. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">Regulatory review by the EMA of the CodeBreaK 200 Phase 3 study of adults with previously treated locally advanced or metastatic KRAS G12C&#8211;mutated NSCLC concluded with the conditional status of marketing authorization maintained.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">CodeBreaK 202 (CB202), a Phase 3 study of LUMAKRAS plus chemotherapy vs. pembrolizumab plus chemotherapy, is enrolling patients with first-line KRAS G12C&#8211;mutated and PD-L1 negative advanced NSCLC.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The ongoing CB202 study is being conducted to serve as confirmatory study and to support conversion of accelerated&#47;conditional approval to full approval, in the US, EU and other regions where applicable.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Nplate </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">The primary analysis of a Phase 3 study of Nplate as supportive care in chemotherapy-induced thrombocytopenia in gastrointestinal malignancies is complete. The Company continues to follow patients through a planned final analysis in H1 2025. Data presentation at a medical congress is anticipated in mid-2025.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Biosimilars </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A randomized, double-blind pharmacokinetic similarity study of ABP&#8239;206 compared with OPDIVO</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (nivolumab) is enrolling patients with resected stage&#8239;III or stage&#8239;IV melanoma in the adjuvant setting. Data readout is anticipated in H2 2025.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A randomized, double-blind comparative clinical study of ABP&#8239;206 compared with OPDIVO is enrolling patients with treatment-na&#239;ve unresectable or metastatic melanoma. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A randomized, double-blind pharmacokinetic similarity study of ABP 234 compared with KEYTRUDA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (pembrolizumab) is enrolling patients with early-stage non-squamous non-small cell lung cancer as adjuvant treatment.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A randomized, double-blind combined pharmacokinetic&#47;comparative clinical study of ABP 234 compared to KEYTRUDA is enrolling patients with advanced or metastatic non-squamous non-small cell lung cancer.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:11.34pt">A randomized, double-blind, pharmacokinetic similarity&#47;comparative clinical study of ABP 692 and OCREVUS</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (ocrelizumab) was initiated and is currently enrolling patients with relapsing-remitting multiple sclerosis. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">TEZSPIRE is being developed in collaboration with AstraZeneca.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">AMG 104 is being developed in collaboration with AstraZeneca.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Rocatinlimab, formerly AMG 451&#47;KHK4083, is being developed in collaboration with Kyowa Kirin.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Ordesekimab, formerly AMG 714 and also known as PRV-015, is being developed in collaboration with Provention Bio, a Sanofi Company. For the purposes of the collaboration, Provention Bio conducts a clinical trial and leads certain development and regulatory activities for the program.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Xaluritamig, formerly AMG 509, is being developed pursuant to a research collaboration with Xencor, Inc. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">IDE397 is an investigational MAT2A inhibitor from IDEAYA Biosciences.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">OPDIVO is a registered trademark of Bristol-Myers Squibb Company.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">KEYTRUDA is a registered trademark of Merck &#38; Co., Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">OCREVUS is a registered trademark of Genentech, Inc. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="icaa4bd57b13d49fe85974fadacdcc0a8_16"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 17</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In this news release, management has presented its operating results for the fourth quarters and full years of 2024 and 2023, in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and on a non-GAAP basis. In addition, management has presented its full year 2025 EPS and tax guidance in accordance with GAAP and on a non-GAAP basis. These non-GAAP financial measures are computed by excluding certain items related to acquisitions, divestitures, restructuring and certain other items from the related GAAP financial measures. Management has presented Free Cash Flow (FCF), which is a non-GAAP financial measure, for the fourth quarters and full years of 2024 and 2023. FCF is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP. Management has also presented Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) and debt leverage ratio for 2024, both of which are non-GAAP financial measures. EBITDA is computed by adding interest expense, provision for income taxes, and depreciation and amortization expense to GAAP net income. Debt leverage ratio is calculated as the ratio of GAAP total debt to EBITDA.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company believes that its presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses certain non-GAAP financial measures to enhance an investor&#8217;s overall understanding of the financial performance and prospects for the future of the Company&#8217;s normal and recurring business activities by facilitating comparisons of results of normal and recurring business operations among current, past and future periods. The Company believes that FCF provides a further measure of the Company&#8217;s liquidity. The Company believes its debt leverage ratio provides a supplemental operating metric for the full year period as it compares the amount of cash generated by our operations for the year.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company uses the non-GAAP financial measures set forth in the news release in connection with its own budgeting and financial planning internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Amgen</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8217;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">s toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what</font><font style="background-color:#ffffff;color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8217;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">s known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In 2024, Amgen was named one of the &#8220;World&#8217;s Most Innovative Companies&#8221; by Fast Company and one of &#8220;America&#8217;s Best Large Employers&#8221; by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, and it is also part of the Nasdaq-100 Index</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube and Threads.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 18</font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon (including the prospective performance and outlook of Horizon's business, performance and opportunities and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 19</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain&#59; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">###</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONTACT&#58; Amgen, Thousand Oaks</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Elissa Snook, 609-251-1407 (media)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Justin Claeys, 805-313-9775 (investors)</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="icaa4bd57b13d49fe85974fadacdcc0a8_19"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 20</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc. </font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Statements of Income - GAAP</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In millions, except per-share data)</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br>December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve months ended<br>December 31,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,716&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,833&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,026&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,910&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,086&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,196&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,424&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,190&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,858&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,451&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,724&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,964&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,784&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,274&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,096&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,179&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,775&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,925&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,166&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,293&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,311&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,258&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,897&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(747)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(821)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,155)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,875)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(782)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,833&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,609&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,855&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">627&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,090&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,717&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.62&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.56&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.42&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.56&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.49&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in calculation of earnings per share&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="icaa4bd57b13d49fe85974fadacdcc0a8_22"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 21</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidated Balance Sheets - GAAP</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In millions)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:64.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,973&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,944&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,782&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,268&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,998&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,518&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,277&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,602&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,030&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,332&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,543&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,941&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,699&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,641&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,637&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,629&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,930&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,611&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,839&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,154&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,549&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,949&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,550&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,099&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,392&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,549&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,170&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred tax liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,616&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,354&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term tax liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,680&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,349&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,326&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,877&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,232&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,839&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,154&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares outstanding</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="icaa4bd57b13d49fe85974fadacdcc0a8_25"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 22</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliations</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Dollars in millions)</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Three months ended<br>December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Twelve months ended<br>December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP cost of sales</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,112&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,112&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,858&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,451&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to cost of sales&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,576)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,834)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,122)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,842)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to cost of sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,576)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,834)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,122)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,878)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP cost of sales</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,536&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,278&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,736&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,573&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP cost of sales as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(23.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(22.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(14.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP cost of sales as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.6&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.3&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.0&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP research and development expenses</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,724&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,534&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,964&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,784&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to research and development expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (b)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(28)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(86)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(55)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(12)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(29)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to research and development expenses</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(86)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(84)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP research and development expenses</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,698&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,494&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,878&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,700&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP research and development expenses as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (b)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP research and development expenses as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19.1&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18.4&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP selling, general and administrative expenses</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,878&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,274&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,096&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,179&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to selling, general and administrative expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (c)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(59)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(510)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(314)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(648)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(13)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to selling, general and administrative expenses</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(59)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(510)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(314)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(661)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP selling, general and administrative expenses</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,819&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,764&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,782&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,518&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP selling, general and administrative expenses as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition-related expenses (c)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6.5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1.0)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2.4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP selling, general and administrative expenses as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20.9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">21.2&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20.5&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP operating expenses</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,775&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,925&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26,166&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,293&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to operating expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to cost of sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,576)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,834)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,122)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,878)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to research and development expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(26)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(86)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(84)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to selling, general and administrative expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(59)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(510)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(314)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(661)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives (d)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(40)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(36)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(185)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain other expenses (e)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(21)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(212)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(694)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to operating expenses</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,722)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,389)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7,770)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5,502)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP operating expenses</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,053&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,536&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18,396&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,791&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 23</font></div></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Three months ended<br>December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Twelve months ended<br>December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP operating income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,311&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,271&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,258&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,897&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to operating expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,722&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,389&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,770&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,502&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP operating income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,033&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,660&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,028&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,399&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP operating income as a percentage of product sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to cost of sales</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to research and development expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to selling, general and administrative expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain net charges pursuant to our restructuring and cost-savings initiatives (d)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Certain other expenses (e)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP operating income as a percentage of product sales</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46.3&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46.7&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP interest expense, net</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(747)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(821)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,155)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,875)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to interest expense, net&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest expense on acquisition-related debt (f)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">807&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP interest expense, net</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(747)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(802)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(3,155)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,068)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP other (expense) income, net</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(782)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">402&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">506&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,833&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to other (expense) income, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest income and other expenses on acquisition-related debt (f)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(18)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(625)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net losses (gains) from equity investments (g)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">875&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(217)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1,522)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to other (expense) income, net</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">875&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(235)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,147)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP other income, net</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">688&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">686&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP income before income taxes</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">782&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">852&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,609&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,855&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to income before income taxes&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to operating expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,722&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,389&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,770&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,502&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to interest expense, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">807&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to other income, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">875&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(235)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2,147)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to income before income taxes</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,597&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,173&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,952&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,162&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP income before income taxes</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,379&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,025&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,561&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,017&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP provision for income taxes</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">155&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">519&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,138&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to provision for income taxes&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax effect of the above adjustments (h)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">537&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">404&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,544&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">846&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other income tax adjustments (i)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(192)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(236)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to provision for income taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">345&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">397&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,308&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">845&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP provision for income taxes</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">500&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">482&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,827&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,983&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP tax as a percentage of income before taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to provision for income taxes&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax effect of the above adjustments (h)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other income tax adjustments (i)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5.7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(0.2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1.9)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to provision for income taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5.0)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3.2&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2.0&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP tax as a percentage of income before taxes</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.8&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15.9&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16.5&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP net income</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">627&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">767&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,090&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,717&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Adjustments to net income&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adjustments to income before income taxes, net of the income tax effect</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,060&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,769&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,408&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,316&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other income tax adjustments (i)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">192&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">236&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total adjustments to net income</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,252&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,776&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,644&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,317&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP net income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,879&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,543&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,734&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,034&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Note&#58; Numbers may not add due to rounding</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="icaa4bd57b13d49fe85974fadacdcc0a8_28"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 24</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In millions, except per-share data)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents the computations for GAAP and non-GAAP diluted earnings per share&#58;</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:54.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.386%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.386%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.386%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.390%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three months ended<br>December 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three months ended<br>December 31, 2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,879&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">767&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,543&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">542&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted EPS</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.16&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.31&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.42&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.71&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Twelve months ended<br>December 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Twelve months ended<br>December 31, 2023</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-GAAP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,090&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,734&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,717&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,034&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares for diluted EPS</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">541&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted EPS</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.56&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.84&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.49&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.65&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:3.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The adjustments related primarily to noncash amortization of intangible assets and fair value step-up of inventory acquired from business acquisitions.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three and twelve months ended December 31, 2024, the adjustments related primarily to acquisition-related costs related to our Horizon acquisition. For the three months ended December 31, 2023, the adjustments related primarily to acquisition-related costs related to our Horizon acquisition. For the twelve months ended December 31, 2023, the adjustments related primarily to noncash amortization of intangible assets acquired from business acquisitions.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(c)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three and twelve months ended December 31, 2024 and 2023, the adjustments related primarily to acquisition-related costs related to our Horizon acquisition.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(d)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three and twelve months ended December 31, 2024 and 2023, the adjustments related to separation costs associated with our restructuring plan and other cost-savings initiatives.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(e)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the twelve months ended December 31, 2024, the adjustments related primarily to impairment charges for IPR&#38;D intangible assets related to our Teneobio, Inc. acquisition from 2021. For the twelve months ended December 31, 2023, the adjustments related primarily to a net IPR&#38;D intangible asset impairment charge for AMG 340.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(f)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three and twelve months ended December 31, 2023, the adjustments included (i) interest expense and income on senior notes issued in March 2023 and (ii) debt issuance costs and other fees related to our bridge credit and term loan credit agreements, incurred prior to the closing of our acquisition of Horizon.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(g)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">For the three and twelve months ended December 31, 2024, the adjustments related primarily to our BeiGene equity fair value adjustment. For the twelve months ended December 31, 2023, the adjustments related primarily to our BeiGene equity fair value adjustment.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(h)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The tax effect of the adjustments between our GAAP and non-GAAP results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Generally, the tax impact of adjustments, including the amortization of intangible assets and acquired inventory, gains and losses on our investments in equity securities and expenses related to restructuring and cost-savings initiatives, depends on whether the amounts are deductible in the respective tax jurisdictions and the applicable tax rate(s) in those jurisdictions. Due to these factors, the effective tax rate for the adjustments to our GAAP income before income taxes for the three and twelve months ended December 31, 2024, was 20.7% and 19.4%, respectively, compared to 18.6% and 20.3% for the corresponding periods of the prior year.</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(i)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The adjustments related to certain acquisition items, prior period and other items excluded from GAAP earnings.</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="icaa4bd57b13d49fe85974fadacdcc0a8_31"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 25</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliations of Cash Flows </font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(In millions)</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"></td><td style="width:52.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.501%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.501%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.450%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.591%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.453%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br>December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve months ended<br>December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,771&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,490&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,471&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(402)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,089)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,046)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,204)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,407)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,754&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,415)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,048&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in cash and cash equivalents</font></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,962&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,797)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,029&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,315&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,011&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,741&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,944&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,629&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,973&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,944&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,973&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,944&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three months ended<br>December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve months ended<br>December 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,771&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,490&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,471&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,096)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,112)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free cash flow</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,394&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,359&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="icaa4bd57b13d49fe85974fadacdcc0a8_40"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 26</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of GAAP Net Income to EBITDA and Debt Leverage Ratio Calculation</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Dollars in millions)</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.520%"><tr><td style="width:1.0%"></td><td style="width:75.737%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.063%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve months ended December 31, 2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP Net Income</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,090&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,592&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,155&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA</font><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,356&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,550&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,549&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total GAAP Debt</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,099&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total GAAP Debt</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,099&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EBITDA</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,356&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Debt leverage ratio</font></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.421%"><tr><td style="width:1.0%"></td><td style="width:7.507%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.511%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 5.5pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:8pt;font-weight:400;line-height:107%">2024 EBITDA includes amortization of inventory step-up of $2.4 billion and net losses from equity investments of $182 million.</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="icaa4bd57b13d49fe85974fadacdcc0a8_34"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Page 27</font></div></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Amgen Inc.</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of GAAP EPS Guidance to Non-GAAP </font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EPS Guidance for the Year Ending December 31, 2025</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:74.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GAAP diluted EPS guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.89&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Known adjustments to arrive at non-GAAP*&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related expenses (a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.06&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP diluted EPS guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.00&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.20&#160;</font></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">* The known adjustments are presented net of their related tax impact, which amount to approximately $1.54 per share.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(a) The adjustments include noncash amortization of intangible assets and fair value step-up of inventory acquired in business acquisitions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Our GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may occur subsequent to this press release such as acquisitions, asset impairments, litigation, changes in fair value of our contingent consideration obligations and changes in fair value of our equity investments. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reconciliation of GAAP Tax Rate Guidance to Non-GAAP</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tax Rate Guidance for the Year Ending December 31, 2025</font></div><div><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:74.817%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP tax rate guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rate of known adjustments discussed above</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP tax rate guidance</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Century Gothic',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>amgn-20250204.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:66a43e5f-8b4e-44fe-ab55-0db62824ab75,g:f296f254-0b7c-4964-aa80-33e600c2767c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:amgn="http://www.amgen.com/20250204" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amgen.com/20250204">
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20250204_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20250204_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="amgn-20250204_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPageDocument" roleURI="http://www.amgen.com/role/CoverPageDocument">
        <link:definition>0000001 - Document - Cover Page Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="amgn_CoverPageAbstract" abstract="true" name="CoverPageAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="amgn_A2.00SeniorNotesDue2026Member" abstract="true" name="A2.00SeniorNotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>amgn-20250204_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:66a43e5f-8b4e-44fe-ab55-0db62824ab75,g:f296f254-0b7c-4964-aa80-33e600c2767c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amgen.com/role/CoverPageDocument" xlink:type="simple" xlink:href="amgn-20250204.xsd#CoverPageDocument"/>
  <link:definitionLink xlink:role="http://www.amgen.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_6686190d-ae03-4cf7-9db7-2e1bdd3e467d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntitiesTable_6686190d-ae03-4cf7-9db7-2e1bdd3e467d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_d4c2a36c-0d87-4c67-9737-e55471ab427c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_6686190d-ae03-4cf7-9db7-2e1bdd3e467d" xlink:to="loc_dei_EntityListingsExchangeAxis_d4c2a36c-0d87-4c67-9737-e55471ab427c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_d4c2a36c-0d87-4c67-9737-e55471ab427c_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_d4c2a36c-0d87-4c67-9737-e55471ab427c" xlink:to="loc_dei_ExchangeDomain_d4c2a36c-0d87-4c67-9737-e55471ab427c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_d9cd4ccc-214f-4fda-825c-b01090146bbd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_d4c2a36c-0d87-4c67-9737-e55471ab427c" xlink:to="loc_dei_ExchangeDomain_d9cd4ccc-214f-4fda-825c-b01090146bbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_7ecfa689-859c-4cde-8b78-e5e8261f6d58" xlink:href="https://xbrl.sec.gov/exch/2024/exch-2024.xsd#exch_XNGS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_d9cd4ccc-214f-4fda-825c-b01090146bbd" xlink:to="loc_exch_XNGS_7ecfa689-859c-4cde-8b78-e5e8261f6d58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7c4b67ae-aad8-481d-868d-1d743bf5c6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_6686190d-ae03-4cf7-9db7-2e1bdd3e467d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7c4b67ae-aad8-481d-868d-1d743bf5c6d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7c4b67ae-aad8-481d-868d-1d743bf5c6d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7c4b67ae-aad8-481d-868d-1d743bf5c6d5" xlink:to="loc_us-gaap_ClassOfStockDomain_7c4b67ae-aad8-481d-868d-1d743bf5c6d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_437f9811-7a75-4086-b334-1870692d1761" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7c4b67ae-aad8-481d-868d-1d743bf5c6d5" xlink:to="loc_us-gaap_ClassOfStockDomain_437f9811-7a75-4086-b334-1870692d1761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_201d08cd-d4aa-4eb8-a0f0-1ea964b3869a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_437f9811-7a75-4086-b334-1870692d1761" xlink:to="loc_us-gaap_CommonStockMember_201d08cd-d4aa-4eb8-a0f0-1ea964b3869a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_b62ab5de-bcde-4459-b7ae-f549eb5254ad" xlink:href="amgn-20250204.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_437f9811-7a75-4086-b334-1870692d1761" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_b62ab5de-bcde-4459-b7ae-f549eb5254ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9cb404ff-9ca8-459e-92b5-b2ee817cf3e5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityCentralIndexKey_9cb404ff-9ca8-459e-92b5-b2ee817cf3e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_76baa2cc-7fae-4d93-a39b-13a3bee463b4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_AmendmentFlag_76baa2cc-7fae-4d93-a39b-13a3bee463b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7ce8a4a7-2824-41e1-9f01-aa32278f5d87" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_SecurityExchangeName_7ce8a4a7-2824-41e1-9f01-aa32278f5d87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_8a0dc23d-a884-400d-8708-2f41d7e3a789" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_8a0dc23d-a884-400d-8708-2f41d7e3a789" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_34e38e25-ef0b-4744-bf22-56f704ce76d1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_PreCommencementTenderOffer_34e38e25-ef0b-4744-bf22-56f704ce76d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_7fcdda8d-58bf-4d7e-a013-ce878f607120" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_SolicitingMaterial_7fcdda8d-58bf-4d7e-a013-ce878f607120" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_7cbe66ff-4b9f-4c6a-bfe3-503540fc8b24" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_WrittenCommunications_7cbe66ff-4b9f-4c6a-bfe3-503540fc8b24" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9663b0df-f93a-44f7-a425-8d8aa78fa861" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9663b0df-f93a-44f7-a425-8d8aa78fa861" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_decf1ff2-65e6-4eb0-b068-88eda1e9f1f3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_DocumentType_decf1ff2-65e6-4eb0-b068-88eda1e9f1f3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8f88f390-da30-4cd9-bd6d-2c222fea101d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_DocumentPeriodEndDate_8f88f390-da30-4cd9-bd6d-2c222fea101d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4d09652a-3704-4a6e-a434-fc84fe403bb8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityRegistrantName_4d09652a-3704-4a6e-a434-fc84fe403bb8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ad9dbc68-2479-4781-8cfb-bd00c569c40a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityFileNumber_ad9dbc68-2479-4781-8cfb-bd00c569c40a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_cde5c43f-9c5f-494a-aaf7-7fa782b4fc1e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityTaxIdentificationNumber_cde5c43f-9c5f-494a-aaf7-7fa782b4fc1e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6f007e96-36cd-4dfe-93aa-03219f887eee" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityAddressAddressLine1_6f007e96-36cd-4dfe-93aa-03219f887eee" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fc879b9f-beaa-4937-b1e0-d51df9569591" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityAddressCityOrTown_fc879b9f-beaa-4937-b1e0-d51df9569591" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c08ebde0-f878-49c3-88a6-9aefd7ebfe71" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityAddressStateOrProvince_c08ebde0-f878-49c3-88a6-9aefd7ebfe71" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fdac6f49-eab1-453b-9f4d-3fd2a07367d4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityAddressPostalZipCode_fdac6f49-eab1-453b-9f4d-3fd2a07367d4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f2f27c00-a29b-41db-ac9e-45241a2dcdb4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_CityAreaCode_f2f27c00-a29b-41db-ac9e-45241a2dcdb4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_823caa5d-cbd9-4038-aab2-af589cf93c2f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_LocalPhoneNumber_823caa5d-cbd9-4038-aab2-af589cf93c2f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_90c6b1b5-7a88-477b-9394-6f37d1d70b00" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityEmergingGrowthCompany_90c6b1b5-7a88-477b-9394-6f37d1d70b00" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4526b584-b788-44e3-9cbb-7605088377e5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_TradingSymbol_4526b584-b788-44e3-9cbb-7605088377e5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_07b1d4a9-d31f-4645-9cf8-718433d93ea6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_Security12bTitle_07b1d4a9-d31f-4645-9cf8-718433d93ea6" xlink:type="arc" order="21"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>amgn-20250204_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:66a43e5f-8b4e-44fe-ab55-0db62824ab75,g:f296f254-0b7c-4964-aa80-33e600c2767c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ClassOfStockDomain_627c081b-5c2b-4b51-843a-88013266ba59_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_21c1f6b9-62bf-4672-b762-1796006a0097_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_1d549d4e-f919-4510-99d9-52a3ecbd9144_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_e48a0b9b-d82f-4fe7-a522-6d4201a4a8d5_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_e3303c43-71f3-4457-8f63-7016c3643f43_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_876148fc-8eed-4127-b87f-df58f33b3767_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_034ebdb9-5109-4244-a458-a54f2ab307a4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_44097fef-5f5d-4aa4-a8f6-a6005925e6a2_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c94dd1b2-ca5e-454d-b12c-5c9d14010a29_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_0ca2eaef-5058-4710-bb75-83e07dd34654_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8478bd55-4314-4b16-a5b3-7f857117e4e8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e141b734-b924-475f-8ab9-18e71b64e62d_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_79e918c8-acc5-4152-ab13-f25ff2824ce6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_7bbfdc66-de56-4aa3-bd9c-e35879742bfa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_0088e736-6f40-4886-b3c5-3bd6cb862daf_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_0a584734-757b-4364-a518-79e8ea803476_terseLabel_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_label_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:label id="lab_amgn_A2.00SeniorNotesDue2026Member_documentation_en-US" xlink:label="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.00% Senior Notes Due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:href="amgn-20250204.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_A2.00SeniorNotesDue2026Member" xlink:to="lab_amgn_A2.00SeniorNotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_99e23468-031b-41ce-a29d-1896309455a2_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_amgn_CoverPageAbstract_49948762-205e-4f43-864f-40a7e5122099_terseLabel_en-US" xlink:label="lab_amgn_CoverPageAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover Page [Abstract]</link:label>
    <link:label id="lab_amgn_CoverPageAbstract_label_en-US" xlink:label="lab_amgn_CoverPageAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover Page [Abstract]</link:label>
    <link:label id="lab_amgn_CoverPageAbstract_documentation_en-US" xlink:label="lab_amgn_CoverPageAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cover Page [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CoverPageAbstract" xlink:href="amgn-20250204.xsd#amgn_CoverPageAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_amgn_CoverPageAbstract" xlink:to="lab_amgn_CoverPageAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c3f2b0e6-fcb9-45ac-9295-0fde36fe1adc_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e467467e-4c52-4ea4-aff8-9fd63245b2fd_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c1607fe4-e3cc-4a12-b912-1ffc7ac56517_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_9b89ba36-4afa-4b42-b3fb-1dd1e2dfa85d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5bcb4aaa-9f74-443d-b530-1d838d853518_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9d3882f2-0466-4b4f-a20b-86ee22fd65df_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_5cb56a41-181e-4eaf-b87b-d9c2ca78b4d3_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b217639f-3e3c-4658-810c-3e47fc6154eb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_88d0733a-5220-4102-a822-3720f2d62d7c_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_76f07961-7bc1-43c2-8763-86081f38e991_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6c9dba24-d740-4e80-b07b-3db94b38bd69_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_e71055ff-7195-44d4-a1cf-78a374eb5dbf_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4d4cfaa1-b639-42c5-84a5-4b092e0bef8e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNGS_f60ee231-b6a3-4371-9cb6-aacbc5e12a08_terseLabel_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]</link:label>
    <link:label id="lab_exch_XNGS_label_en-US" xlink:label="lab_exch_XNGS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS" xlink:href="https://xbrl.sec.gov/exch/2024/exch-2024.xsd#exch_XNGS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNGS" xlink:to="lab_exch_XNGS" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>amgn-20250204_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:66a43e5f-8b4e-44fe-ab55-0db62824ab75,g:f296f254-0b7c-4964-aa80-33e600c2767c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amgen.com/role/CoverPageDocument" xlink:type="simple" xlink:href="amgn-20250204.xsd#CoverPageDocument"/>
  <link:presentationLink xlink:role="http://www.amgen.com/role/CoverPageDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_amgn_CoverPageAbstract_190d9ce4-8a1a-4f14-af55-451a3ea8b4ef" xlink:href="amgn-20250204.xsd#amgn_CoverPageAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_6686190d-ae03-4cf7-9db7-2e1bdd3e467d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_amgn_CoverPageAbstract_190d9ce4-8a1a-4f14-af55-451a3ea8b4ef" xlink:to="loc_dei_EntitiesTable_6686190d-ae03-4cf7-9db7-2e1bdd3e467d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_d4c2a36c-0d87-4c67-9737-e55471ab427c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_6686190d-ae03-4cf7-9db7-2e1bdd3e467d" xlink:to="loc_dei_EntityListingsExchangeAxis_d4c2a36c-0d87-4c67-9737-e55471ab427c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_d9cd4ccc-214f-4fda-825c-b01090146bbd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_d4c2a36c-0d87-4c67-9737-e55471ab427c" xlink:to="loc_dei_ExchangeDomain_d9cd4ccc-214f-4fda-825c-b01090146bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNGS_7ecfa689-859c-4cde-8b78-e5e8261f6d58" xlink:href="https://xbrl.sec.gov/exch/2024/exch-2024.xsd#exch_XNGS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_d9cd4ccc-214f-4fda-825c-b01090146bbd" xlink:to="loc_exch_XNGS_7ecfa689-859c-4cde-8b78-e5e8261f6d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7c4b67ae-aad8-481d-868d-1d743bf5c6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_6686190d-ae03-4cf7-9db7-2e1bdd3e467d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7c4b67ae-aad8-481d-868d-1d743bf5c6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_437f9811-7a75-4086-b334-1870692d1761" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7c4b67ae-aad8-481d-868d-1d743bf5c6d5" xlink:to="loc_us-gaap_ClassOfStockDomain_437f9811-7a75-4086-b334-1870692d1761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_201d08cd-d4aa-4eb8-a0f0-1ea964b3869a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_437f9811-7a75-4086-b334-1870692d1761" xlink:to="loc_us-gaap_CommonStockMember_201d08cd-d4aa-4eb8-a0f0-1ea964b3869a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_amgn_A2.00SeniorNotesDue2026Member_b62ab5de-bcde-4459-b7ae-f549eb5254ad" xlink:href="amgn-20250204.xsd#amgn_A2.00SeniorNotesDue2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_437f9811-7a75-4086-b334-1870692d1761" xlink:to="loc_amgn_A2.00SeniorNotesDue2026Member_b62ab5de-bcde-4459-b7ae-f549eb5254ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_6686190d-ae03-4cf7-9db7-2e1bdd3e467d" xlink:to="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9cb404ff-9ca8-459e-92b5-b2ee817cf3e5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityCentralIndexKey_9cb404ff-9ca8-459e-92b5-b2ee817cf3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_76baa2cc-7fae-4d93-a39b-13a3bee463b4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_AmendmentFlag_76baa2cc-7fae-4d93-a39b-13a3bee463b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7ce8a4a7-2824-41e1-9f01-aa32278f5d87" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_SecurityExchangeName_7ce8a4a7-2824-41e1-9f01-aa32278f5d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_8a0dc23d-a884-400d-8708-2f41d7e3a789" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_8a0dc23d-a884-400d-8708-2f41d7e3a789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_34e38e25-ef0b-4744-bf22-56f704ce76d1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_PreCommencementTenderOffer_34e38e25-ef0b-4744-bf22-56f704ce76d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_7fcdda8d-58bf-4d7e-a013-ce878f607120" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_SolicitingMaterial_7fcdda8d-58bf-4d7e-a013-ce878f607120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_7cbe66ff-4b9f-4c6a-bfe3-503540fc8b24" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_WrittenCommunications_7cbe66ff-4b9f-4c6a-bfe3-503540fc8b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9663b0df-f93a-44f7-a425-8d8aa78fa861" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9663b0df-f93a-44f7-a425-8d8aa78fa861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_decf1ff2-65e6-4eb0-b068-88eda1e9f1f3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_DocumentType_decf1ff2-65e6-4eb0-b068-88eda1e9f1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8f88f390-da30-4cd9-bd6d-2c222fea101d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_DocumentPeriodEndDate_8f88f390-da30-4cd9-bd6d-2c222fea101d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4d09652a-3704-4a6e-a434-fc84fe403bb8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityRegistrantName_4d09652a-3704-4a6e-a434-fc84fe403bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ad9dbc68-2479-4781-8cfb-bd00c569c40a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityFileNumber_ad9dbc68-2479-4781-8cfb-bd00c569c40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_cde5c43f-9c5f-494a-aaf7-7fa782b4fc1e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityTaxIdentificationNumber_cde5c43f-9c5f-494a-aaf7-7fa782b4fc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6f007e96-36cd-4dfe-93aa-03219f887eee" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityAddressAddressLine1_6f007e96-36cd-4dfe-93aa-03219f887eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_fc879b9f-beaa-4937-b1e0-d51df9569591" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityAddressCityOrTown_fc879b9f-beaa-4937-b1e0-d51df9569591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c08ebde0-f878-49c3-88a6-9aefd7ebfe71" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityAddressStateOrProvince_c08ebde0-f878-49c3-88a6-9aefd7ebfe71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fdac6f49-eab1-453b-9f4d-3fd2a07367d4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityAddressPostalZipCode_fdac6f49-eab1-453b-9f4d-3fd2a07367d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f2f27c00-a29b-41db-ac9e-45241a2dcdb4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_CityAreaCode_f2f27c00-a29b-41db-ac9e-45241a2dcdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_823caa5d-cbd9-4038-aab2-af589cf93c2f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_LocalPhoneNumber_823caa5d-cbd9-4038-aab2-af589cf93c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_90c6b1b5-7a88-477b-9394-6f37d1d70b00" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_EntityEmergingGrowthCompany_90c6b1b5-7a88-477b-9394-6f37d1d70b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4526b584-b788-44e3-9cbb-7605088377e5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_TradingSymbol_4526b584-b788-44e3-9cbb-7605088377e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_07b1d4a9-d31f-4645-9cf8-718433d93ea6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_abb97e31-a5b7-4f49-ba90-e7f864b60682" xlink:to="loc_dei_Security12bTitle_07b1d4a9-d31f-4645-9cf8-718433d93ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>amgenlogoa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 amgenlogoa.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ") ;H# 2(  A$! Q$!_\0
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M-<?\)!"V[_EDUE"4'T&VOG^BOJ(Y+EL598>'_@*/G)9MF$G=UY?>SZC\-_\
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M]P**** "BBB@ K!\=>--,^'OA+4_$.KSI;V-C"TKLQQN/\*C@\L< <=ZWJ^
M/^"B'QH_M/6K'X>:9<9MK'%UJ?EN<-*1\D9P>=H.X@CJ5/:O;R;+99IC(8=?
M#NWV2W_R]3Q\VS".6X25=[[+S;_JY\N_%SXGZI\7O'FI^)-49@]U(?)M_,9T
MMX_X8USV KC:**_HZG3A1@J=-6BM$C\#J5)59NI-W;U85]/?LI_L=W?QB*>(
M_$XN--\((V(E3Y);]@>0A(X0'@MWZ#G)&+^R3^S+>_&WQ1%JVJ6[1>"].F!N
MYFR/M3C!\A/4G(W$?=!]2*_4BQLK?3;."TM(([:UMXUBBAB4*D:*,!5 Z  8
MQ7Y]Q-Q$\%?!X1_O'N_Y?+U_+UV^XX>R%8RV*Q2]SHOYO/T_/TW_ "F_;,\.
MZ9X1^-UYHVCV4.GZ99V=M%!;PKA441C\R3DDGDDDUX97T+^W?_R<5K/_ %[V
M_P#Z+%?/5?7Y3)RR^A*3NW&/Y'RV:14<=6C%62D_S%7[P^M?IG\8/^3#;+_L
M7-,_]%PU^9B_>'UK],_C!_R8;9?]BYIG_HN&OG>)/X^!_P"OB_0][A_^#C/^
MO;_4_,NBBBON#XX**W/"_@G6?&BZM_8UD]\^EV+ZC<QQXW+ C*KN!WQO!..V
M3VK#J5*,FXIZK<IQDDI-:,[/X/\ Q(OOA/\ $/1_$MB[!K28>;&"0)8CPZ$
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ME\9_^AVF_P# &U_^-5]5]3XG_P"@J'W+_P"0/F_K7#O_ $#3^_\ ^W/>(_\
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M10 44NT^E&T^E "5^J_[,/\ R:#H/_8-OO\ T=/7Y4[3Z5^JW[,/_)H6@_\
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MB[/Y"K]X?6OTS^,'_)AME_V+FF?^BX:_,Q?O#ZU^F?Q@_P"3#;+_ +%S3/\
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MN*JU*=/1R;7O+9OU/V3!Y]E=+#4J<ZFJBD]'NEZ'VI_PCND_] NS_P# =/\
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M ,M@HHHKZ \,_2O_ ()T_P#)$=0_["TG_HN.OJBOE?\ X)T_\D1U#_L+2?\
MHN.OJBOYRX@_Y&F(_P 3/WS(_P#D6T/\*"BBBOGSW HHHH *_.?_ (*.>/CK
M7Q*TCPM$Y,&B6GF2*T8!$TV&.&[C8(OH<U^BEQ<16=O+//(L,$2EY))" JJ!
MDDD] !7XP?&#QDWQ!^)WB7Q"P*+?WTLR(9?,"(6.U0W< 8 ^E?H7!>$]MC98
MAK2"_%Z?E<^%XNQ7LL'&@MYO\%K^=CCZ**OZ!I<FN:Y8:?%D274Z0J0I;EF
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M\T1KTW.BNQ_%F)_&O):]F_;%_P"3D_&__7S'_P"B8Z\9K]ERUN6!H-_R1_\
M24?D^/26,K)?S2_-A7ZP?L2@K^S/X0R,?\?1Y_Z^I:_*!>HK]C/V<[&'3_@/
MX!B@01HVBVLI _O/&&8_B6)_&OB^-YVP5*'>5_N3_P SZ[@^%\94GVC^;7^1
M7_:<_P"3?_'G_8*E_E7X]5^PO[3G_)O_ (\_[!4O\J_'JIX'_P!SJ_XOT0^,
M?][I_P"']6%?67_!-O\ Y+1KG_8"F_\ 1\%?)M?67_!-O_DM&N?]@*;_ -'P
M5]/Q!_R*L1_A_4^=R/\ Y&5#U/H7]M3]FN;XO^'(?$7AVTCD\5Z6F&3)#W=L
M,GRAVW DD?4CO7YES0R6TTD,R-%+&Q5T<8*D<$$>M?NA7R+^U5^Q5!\0&N?%
M7@:WCM?$K-ONM.W!(KW/5E)P$D[]0#['K^?<,<11PJ6!QCM#[,NWD_+L^GIM
M]UQ%D,L0WC,*KR^TN_FO/\_7?\YJ*OZYH.H^&=4N=-U6RFT^_MG,<UO<(4=&
M!P00:H5^P)J2NMC\J:<79BABN0"0*UI_%VN75FUG-K%]+:,NPP/<.4*^F,XQ
M6110TI;H$VMA68MU)/UI***H04Z.-I'5$4LS' 4=2:O:%X?U+Q/JEOINDV,^
MHW]PVR*WMHR[N?0 5^@O[+7[$<'@22#Q/X^MX;SQ C![72]PDAM,=&<CAWST
MQE1[GIXF:9OALII>TK/WND>K_P"!YGKY;E>(S.KR45IU?1?\'R-/]B7]F>?X
M7Z.WB[Q' B^(=2A7[-;L/GLX2,X/HS9&1V QZUP7_!33[O@3_M[_ /:5?=%?
M"_\ P4T^[X$_[>__ &E7Y1DN.K9EG]/$UGJ[_)<KLD?IF;X.E@,CGAZ*T5OF
M^9:L^%****_<3\<"BBB@ K]5_P!F'_DT'0?^P;??^CIZ_*BOU7_9A_Y-!T'_
M +!M]_Z.GKX#C/\ W*E_U\7Y2/M^$_\ >ZO^!_FC\JI/]8WU--ITG^L;ZFFU
M^@/<^'6Q=T7_ )#%C_UW3_T(5^XD?^K7Z5^'>B_\ABQ_Z[I_Z$*_<2/_ %:_
M2OR;CK?#?]O?^VGZ?P9M7_[=_P#;BCX@T6W\2:%J&E7:AK:]@>WDRH;AE(S@
M\9&<U^+7CSPK<^"/&6LZ%=QO%/874D#+)C=PQ )QQTQTK]M:_+_]OKP:?#/Q
MVN;^.TCMK36+:.[1HR/WCXVR,1V.Y37'P3BW3Q53"MZ25_FO^ W]QU<887GP
M]/$+>+M\G_P5^)\V4445^R'Y.?I7_P $Z?\ DB.H?]A:3_T7'7U17RO_ ,$Z
M?^2(ZA_V%I/_ $7'7U17\Y<0?\C3$?XF?OF1_P#(MH?X4%%%%?/GN!1110!1
MUS2+?Q!HM_I=WN^RWMO);2[#AMCJ5;!['!-?/?\ P[_^$W>VU<G_ *_S_P#$
MU])45WX;'XK!IK#U'%/>SL<6(P6&Q33KTU*VUU<^;?\ AW]\)O\ GVU?_P #
MS_\ $UL^#?V*OAKX%\4Z9X@TJ#4UU#3IUN(#+>%TW+TR-O(KWFBNJ6=9C.+C
M*O)I^;.:.4X"$E*-&*:\D%%%%>,>L%%%% 'EOCC]F7X;_$;Q%/KGB'PZM_JD
MX423_:IDW8&!PK@=/:L'_ABOX.?]"BO_ ('7'_QRO<**].&9XZG%0A7DDMDI
M/_,\^678*I)SG1BV_P"ZO\CP_P#X8K^#O_0HK_X'7'_QRO2M6^&WAS7/ L?@
MZ^TU;CPY';Q6BV1D< 11@!%W [N H[]JZ:BLJF/Q=9Q=6K*3CJKMNS[KL73P
M6%HJ2ITHJ^CLDKKS/$O^&+_@W_T)L?\ X&W/_P <H_X8O^#?_0FQ_P#@;<__
M !RO;:*W_M7,/^@B?_@4O\S+^S,#_P ^(?\ @*_R/.?A[^SU\/\ X5ZY)K'A
M?P^FEZC) ULTRW$TA,;,K%<.Y'5%[=J]&HHKAK5ZN(ESUIN3[MW?XG92HTJ$
M>2E%179*QY5XN_9<^&/CKQ%>Z[KGA>.^U6\8//<&ZG3>0 H.%< < =!6/_PQ
M?\&_^A-C_P# VY_^.5[;179',\="*C&O-)?WG_F<LLNP4Y.4J,6W_=7^1XE_
MPQ?\&_\ H38__ VY_P#CE>O:#H=CX9T2PTC3(!:Z=80);6T )(CC10JKDDDX
M '6K]%85\9B<2DJ]64DN[;_,VHX3#X=MT::BWV27Y&9XD\.:=XNT&^T;5K87
M>FWL1AN("S+O0]1E2"/P->2_\,7_  ;_ .A-C_\  VY_^.5[;110QN)PR<:%
M644^S:_(5;"8?$-2K4XR:[I/\SQ+_AB_X-_]";'_ .!MS_\ '*ZGX=_L^^ ?
MA3K,VK>%O#Z:5J$T#6SS+<32$QEE8KAW(ZHI_"O1**UJ9CC:L7"I6DT]TY-K
M\S.GE^#I24Z=&*:ZJ*O^04445YQWG#_$[X+>#OC!IYM?%&BP7TBH4AO%&RXA
MR" 4D'/&XG!RN>H-?)7CO_@FK-]H>;P?XJB:!G=OLNKQ%6C7^!1(@.X]0257
MM7W;17N8'.L?ERY</4:CV>J^Y[?(\;&91@L>^:O3U[K1_>OU/RFUS]A_XO:%
MI\MVWAM;U8R 8[&ZBFD/.,A%;)_*N5_X9A^*W_0AZY_X"/\ X5^P=%?4PXWQ
MT5[].+^]?J?.3X/P;?NU)+[O\C\KM%_85^+NL6]K.VA0V,<^"1=WD2/&">K+
MNW#'IC->V^ ?^":L<-R)O&7BE9H5<_Z+HT9_>+MX_>2#Y3N_V#P/?C[DHKS\
M1Q?FE=<L&H>BU^]W_ [</PMEU%\TDY^K_P K'#_#'X+>#?@_IXM?"^B06,C(
M%EO&'F7,W"@[Y#\V#M!VC"YY %=Q117Q]6M4KS=2K)RD^KU9]53I0HP4*<4D
MNB"N)^)'P7\&_%S[#_PEFBKJWV'?]GW321[-V-WW&&<[1U]*[:BBE6J4)JI2
MDXR75.S"I2IUHN%6*DGT>J/$O^&+_@W_ -";'_X&W/\ \<H_X8O^#?\ T)L?
M_@;<_P#QRO;:*]#^ULP_Z")_^!2_S.+^S,#_ ,^(?^ K_(\2_P"&+_@W_P!"
M;'_X&W/_ ,<H_P"&+_@W_P!";'_X&W/_ ,<KVVBC^ULP_P"@B?\ X%+_ ##^
MS,#_ ,^(?^ K_(\1_P"&+?@Y_P!"<G_@=<__ !RO4/#/@?1/!_A*#PSI%BMG
MHD,;Q1VH=F 5V9F&YB3R6;OWK>HKGK8[%8B*C6JRDEKJV]?F;4<'AL.W*C3C
M%OLDOR/$S^QA\'"23X-CS_U^W/\ \<I/^&+_ (-_]";'_P"!MS_\<KVVBNC^
MULP_Z")_^!2_S,?[,P/_ #XA_P" K_(\5B_8T^#L,J2)X.C#H0P/VVY/(_[:
M5[2..!2T5R5\5B,5;V]1RMM=MV^\Z:.&H8>_L8*-][)+\@K@/B-\!_ WQ:U"
MUOO%>A+JMU:Q>3%(UQ+'M3).,(PSR3U]:[^BLZ-:KAY^THR<9=T[/\#2K1IU
MX\E6*DNS5T>)?\,7_!O_ *$V/_P-N?\ XY1_PQ?\&_\ H38__ VY_P#CE>VT
M5W_VMF'_ $$3_P# I?YG%_9F!_Y\0_\  5_D<O\ #WX9^&_A7HTFE>%]-72[
M"24SM"LKR9<@ G+L3T _*NHHHKSJE2=63G4;;>[>K.^%.%.*A!62Z(****S+
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46396789545936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page Document<br></strong></div></th>
<th class="th"><div>Feb. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000318154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb.  04,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amgen Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3540776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Amgen Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Thousand Oaks<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91320-1799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">447-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNGS', window );">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityListingsExchangeAxis=exch_XNGS', window );">NASDAQ/NGS (GLOBAL SELECT MARKET) [Member] | 2.00% Senior Notes Due 2026 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMGN26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.000% Senior Notes due 2026<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNGS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNGS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=amgn_A2.00SeniorNotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *J 1%H'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "J@$1:!=QB.N\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>.LT82%'7"X@32$A, G&+'&^+:-HH,6KW]J1EZX3@ 3C&_O/Y
ML^0:@\8^TG/L T5VE*Y&WW9)8]B( W/0  D/Y$TJ<Z++S5T?O>'\C'L(!C_,
MGD!)>0.>V%C#!B9@$1:B:&J+&B,9[N,);W'!A\_8SC"+0"UYZCA!558@FFEB
M.(YM#1? !&.*/GT7R"[$N?HG=NZ ."7'Y);4, SEL)IS>8<*WIX>7^9U"]<E
M-AU2_I6<YF.@C3A/?EW=W6\?1*.D6A=2%?)ZJRHMU[JZ?9]<?_A=A'UOW<[]
M8^.S8%/#K[MHO@!02P,$%     @ JH!$6IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "J@$1:AT7ZIOL$  !\%0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+68:V_B.!2&_XK%7C0CE9(X7+N 1(%V45O*%G9'VM%\,(F!J$G,V$YII?WQ
M>QQ"PE;AI*UF^Z'DYC=/;)_W==+="?FH-IQK\AP&D>I5-EIO+VHUY6YXR-2Y
MV/((SJR$#)F&7;FNJ:WDS$L:A4&-6E:S%C(_JO2[R;&9['=%K ,_XC-)5!R&
M3+Y<\D#L>A6[<CCPX*\WVARH];M;MN9SKO_<SB3LU3(5SP]YI'P1$<E7O<K
MOKATD@;)%7_Y?*>.MHEYE*40CV9GXO4JEB'B 7>UD6#P\\2'/ B,$G!\3T4K
MV3U-P^/M@_I5\O#P,$NF^% $7WQ/;WJ5=H5X?,7B0#^(W>\\?:"&T7-%H)+_
M9)=>:U6(&RLMPK0Q$(1^M/]ESVE''#5PZ(D&-&U $^[]C1+*$=.LWY5B1Z2Y
M&M3,1O*H26N \R,S*G,MX:P/[71_*)ZX)#,8 #(2;@S]K;LU#<+F=,U-12[W
M(O2$R!5?GA.K?D:H11O_;5X#G@R*9E TT7-.Z(TC[>L7,HGVL\Z,WM=;N(9,
M- _5MR+ O6"]6-!,[0NU92[O56#N*BZ?>*7_ZT]VT_H-P74R7 =3/^ .H>\D
M"P#;X\_DAK\4<>)*%OPY=MMNU!&L>H951\4&,)B>&5!R%;!U$0S>?L4"Q1&.
M1L;10'5FDE==$0*)RQ.<B5(Q3+H%X,'/_6K%91$=KEI&U\SHFN^C*\/"Y<JP
M6AE6"]69B\!W?>U':W+'-)<^"XI@<)$RF'8&TT9UODA?:QZ1(?13'/EN4I*J
MB ?7*>/I9#R=MQ3<)'*%W J9X)R1N8:.(D("9@R5" 4I/%X$B8N/Q@BA;>6^
M:N$RJ9N2Q<NVD**D?;MZ@W$<^;O]-HX93"+AD7'D$4B*8B1<*K'YQ.?+C-[.
MG=Y&G?DPE ]\[2MP3^"<LK 8#A<:A&N8H3 ESC&NW-+M-WGZE1]P,HW#9;$7
ME(A8EEUU6BV+8DBYG=NX'Z=("_9,)AZ,J+]**Q$#Q"4[C:K3J%NM5A,CS(W>
MQCTY)1QX'H2L.CMLD"2[[Z/B8<4EH179#ZV)5_#ED815'$:;&[^-6_5KVJ'9
M _M8B%U42(K++38B5@RJZYX]*@PPCP ;M^_7@)G!S:1X\B&O"BEQS>$ 0\L#
MP<:=_#7:3"@-2Y^__>U)URU1[-@.M:IVJ]/! /.$L'$73P9S .\IIWEP@;:%
MKF3S'*"XC]\*%SIFMA$19B0E(O5ZJVK#VA CRA.!XC:>CMTXY')MUA?7H* W
M)MRW+"I<M)8(EL4Z/5KWXR8^'<Q'@S]JT^LY^71]>W\YN"7S\>UXN"!W@X>;
M\>(S^7K'31]^(_\DJQ$PO[D6[F-VO!#__W@YH'F44.>'O\V@N?)1XCQI*!X+
M<^[&,IDCS^Z&1?!N>"J42X3VXXDQY=E"\2!82.:9V3I_"9>B<"U<(C"XNYYB
M)'ENT!*C]S4L"L2*V/33\C,Y=%8A$JZ4SF!E9O 9^=DZAQ*WR99)\L2"&"VI
M/$0H;OCO*BD*!+_ $T4^I,Q4:*[(*.9FM=?$*PQE^.A\S=.(MG]XA:%I]%'B
M/)XHGB[OJ#!<J+3"G#RI'#QDRBNL1,!4&,56DDZ>40X>*>^HL1(E,Z5?SVDO
MG=-%J+6C;VGFN^0=,RFI2,!7H&^=M\!EY/Y3WWY'BVWR>6TIM!9ALKGAS./2
M7 #G5P+NF>Z8+W;9!]?^OU!+ P04    " "J@$1:GZ ;\+$"  #B#   #0
M 'AL+W-T>6QE<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV0&&PC4+S85^56'8$
M>O%DN7/ZZZ>S;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\X<BY([V2NMW0HW/-
M^R1I#T>N6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZF
MTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,7
M8&F? KP(&K <XRBAC05C$C*$[_VX_!DP::U7A90SP24-AF+=,.>XU7=>&18/
MQA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<
M45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,
M%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>
M]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M
M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9 ]IV03NA1.XJR
MY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD<VW
ML,\E=,E[7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P/!@#S"=X87G^I_VL
MT/T$#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/
MAG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+
MV.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0
MIA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " "J@$1:EXJ[
M',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6
M!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV
M)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O
M@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=
MI7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (
M *J 1%K;7P?M.0$  # "   /    >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5
M*A^P%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>]I3<V;K<7187XM.!
MZ)1\>1=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y
M&+6VG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q&-#C%<K<9":)-5U>
MB/%*0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\
M@RX/J!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!
M=09#K+&))@G60VY6= 9.MO8(R;C=I=/G-N605-3B36\\1QWPIAS,C@Y+J#!
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MJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%
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M?^:+X3]>?P%02P$"% ,4    " "J@$1:!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *J 1%H%W&(Z
M[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( *J 1%J97)PC$ 8  )PG   3              "  <T!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ JH!$6H=%^J;[!   ?!4
M !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    ( *J 1%J?H!OPL0(  .(,   -              "  3\-  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ JH!$6I>*NQS     $P(   L
M         ( !&Q   %]R96QS+RYR96QS4$L! A0#%     @ JH!$6MM?!^TY
M 0  , (   \              ( !!!$  'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( *J 1%HD'INBK0   /@!   :              "  6H2  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *J 1%IED'F2&0$
M ,\#   3              "  4\3  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     )  D /@(  )D4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>3</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="amgn-20250204.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amgen.com/role/CoverPageDocument</Role>
      <ShortName>Cover Page Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="amgn-20250204.htm">amgn-20250204.htm</File>
    <File>amgn-20250204.xsd</File>
    <File>amgn-20250204_def.xml</File>
    <File>amgn-20250204_lab.xml</File>
    <File>amgn-20250204_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "amgn-20250204.htm": {
   "nsprefix": "amgn",
   "nsuri": "http://www.amgen.com/20250204",
   "dts": {
    "inline": {
     "local": [
      "amgn-20250204.htm"
     ]
    },
    "schema": {
     "local": [
      "amgn-20250204.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "amgn-20250204_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "amgn-20250204_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "amgn-20250204_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 2,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 1,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 3,
   "elementCount": 32,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 27
   },
   "report": {
    "R1": {
     "role": "http://www.amgen.com/role/CoverPageDocument",
     "longName": "0000001 - Document - Cover Page Document",
     "shortName": "Cover Page Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:PreCommencementIssuerTenderOffer",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amgn-20250204.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:PreCommencementIssuerTenderOffer",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "amgn-20250204.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "amgn_A2.00SeniorNotesDue2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.amgen.com/20250204",
     "localname": "A2.00SeniorNotesDue2026Member",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.00% Senior Notes Due 2026 [Member]",
        "label": "2.00% Senior Notes Due 2026 [Member]",
        "documentation": "2.00% Senior Notes Due 2026 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "amgn_CoverPageAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.amgen.com/20250204",
     "localname": "CoverPageAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover Page [Abstract]",
        "label": "Cover Page [Abstract]",
        "documentation": "Cover Page [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Listings, Exchange [Axis]",
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange [Domain]",
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "exch_XNGS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/exch/2024",
     "localname": "XNGS",
     "presentation": [
      "http://www.amgen.com/role/CoverPageDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]",
        "label": "NASDAQ/NGS (GLOBAL SELECT MARKET) [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0000318154-25-000005-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000318154-25-000005-xbrl.zip
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M^_ C!3?$$L#LM?ZZOVMW6Q*8VP#38_\P\+.0,//L^W<+ -KZUNJT>X\2GMO
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MM?KV@T. 2X.+@ME?DV-!Z11<XL/&\!PMPRV0B+ V&6'6UW$0$59CD5Y>!<%
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MQCLF D?[P<9R2\][89(@;--'S-W;_[Q'-!PMW'JWO>;U!I"3P/E0X+Q-KQP
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M&%:^9Z:KVU3B>SMCX$8? _"R.#MA_QKM><0<1C[KL %X/75<XO%6D9]*2H/
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M75Y;%EIF PM'SY&_?>IXJ*C0EN-5'!.&*5>0<IP,\6?X2YG7=% 5K!:-GQ'
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M9'@<ICZ=S]<<8Q5)4 5YTOK<[ETV!1UKK.^!?Q2<A<DM? XP<8@4B) 1 D9
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MTGHV@=JT8(($IZ<IMX3'FW(I;G)C"?E03&MC(E(VPU$! 87$.WO '@H* _L
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MQ&2P8A$;FBN4<GD<R0:OU/2$8IZ_*"KF@5.%A% #<_IDRL:?F8ZY25!5GE;
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MU'I1P8(;\G#(6'>#8^Z0S'%(MR'23MP"G/TT H5[:SCZC)<;FS['*1]4 J^
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M^E'$^#HDO0+Y#XM$FQO$!71L=@71%9V.YN*AKI$:=Q9(--+78GSX#+4M*BT
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MRV%A,N0VA,BZP=%@SU5+\%3@!DL=W $%J$^UA/6:*#(' ?U^O%*0^$'>&F:
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MJ5NT:G;N-H@@ =<O<30C0WF6T&SBT?,J]%D,<#8E+Q'9/3:Y*P(AA&!-R6V
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MT*$-I I2[:]4KY1Z+4IA(I2[:0M51"D%(LBHMMQ24JUM'QMH4BLHL.26$F"
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M4Q(54CT M>^8A*"83Q<W:_\D"CB%HE.=H#5 (:K-R)?9S[(CP*M:0\'A4NV
M@CZ@P#E2WAU0T <4V'W5")"G[\\[A;%\F=6;X GYY$%"#SC$,;W50JQ?SY\&
M89"D,8N.0$TJSLX>]2C?K356&V"AX0EHDF9#'2+  IV +2ENK=0%P$)GL&!)
MJGVX-G!+J:6NU:0ZQ4""\E07?57(1.5A'LM03!Z+66M!@1YF<TQU[T5ND.A9
M$M55Z$E7K40MH]8::D)J!Z"Q'),0E/T!R8)D0;)%537N>G1VL%35)4%_L5.8
M!SP7GNZ0B[X(^[T=6 4>/"18A>:\*FLOCQ,*5YW&\*P@UPU5.SJ0^U E1VVI
M+^+Y&3) 5B>091_I^@/( F2=EZ^U'0V0!<BJH3J:J;99'0VXL?UYIS ^P\G^
M0B_+66GJ$<)_QVG]_8NO:VZ]MW%A11M?44T^;%?"BG9M176Q]ZB01(]>T@ 5
M&9H 5IP-D&OM MA#B:HR,"LK;OPDU\JL%%(]  _PF(2@3!!(%:3:9ZE"2:LZ
M"0]0W6K=R5;DEB@$;;O?P+Y:"Y[UM*(-H& MS=%2:AY0P(]DB$;HZ5G04@:_
M\;1V7U\HC.'+C-Z(V+#$M T?H&X59Z>*)=EVK7R!\YEL@(7&L>!J@ 7  K.L
M+$FUH' 5@"$SLR7-U:%RU>65J[8-(:A/==%7A<P\;H"&IA1IZ%=8SNJ5*IDV
MT%*JEJFC0SFE:F5J2ZH&K88JOM).*R?SDT/LIHHXVBA'2+6A@<ZH5J &\.ZJ
M%:@#"*U8H,!CO%!55%QHJGL0@D*X4 B7<XE"(=P&2S:!XFB$ (^N?#%O5('1
M7+5;!_*L5IN $U)Q:-6I]<:?T,J$/ G'*]=LL9A*0:O5W.CAGJNUQG0/Y:FI
MH&8K=C%<[F)3':R#?IPJ>@JE7>DBJ_U*E>S]:<;2<VUMZPJV&IJD.Z=7H(?5
MJ"L%;]NG5Z*'U:@I]"N92GLGE3"7)!:W@TM?E( RKQW@S9J28AZFS4(!84#6
M.5,S)%,_S,X'9 &RSBJG[TCZD8[E "V UEG0,B3;5:'L>>]*D+?QSMUKK=K5
M+#9\%83.RU=!Z"#T?GP5A Y"[\=70>CM"7W?;_P@F4V\Y]=A%.+#3X=OKG\3
M! N"[=8W0;!U"O:7U"/^._E_/WC\[5?RG\V(C"I3,N,LRIISO&;-.8)'_.8I
M\--Q'DU:_5T6YGFM+'_B#9)H,D^W?Y(%OG[[=4#'D<>@V#^O_G>\T+PS[P%?
M#V+L?;_V1BF.7WN3)^\Y67_]- B+2)=ELZ&7?NN1SXHWK,2Y*%LF&#U7',%3
MU6,A/(W=)?OSC_>?T-W[+Y_O[K^B#Y^_W=W_ _WSV\W=_?L[=//I'?KP[>-'
M]*_W-W=(4S0#?;C]=//I[>W-1_*;K]\^WG_=,_N&I_&%%E/6]%T 6%U6+WX@
M*YN#:R-L3$LRXYA:8Q3+&X$J,HV)-TOPZ^(/;XJ]$(1L-.Q';]9?0'&S$;YD
M[\L^7D)*5C)8Y<=3_N;\8YE]M!%5S3XS'=ERS;T?*[*Z][-#CW5D0]'.>NKA
MSTQ]_SMAK/R-U2WUU)*4C;TFO%N&W9'MS48R'U8YIN,XQAA-R??&"<*ACWUZ
MVK_#0SP=X!CIJE1%!:B.RN8)3QY/$,ZE"-J953C*3^):A%35E@!0J?GV3&YZ
M%1M/3-$ I*J E# <Q0U^8A .HRF^E/DI)".C4Z0,3=+5,SD9?#)^ &*\04R5
M-%LHB(F/K^Z RY8TTQ&&KM@+<'4,7XYKMWMX=;LN=JFB9&?=^NS<=2EVKY.S
MFOHBR)7=T 2YUG#VV39T3:WC7IBIU'\."!-YV'$[$J(/8EA7AJ3H9]Z0! ,>
M(%9F=KID68>5&$ ,(':976]*BG9F$ (P!A@KA3%=TMTSVY]7'(C89.O!_4D!
MWRF,][#3<T!>@CQ$_I$FD"D9,!JA61SY\V$J;ILMS3K2+?O",Z+Y&57<&;US
M*ZI:<JUQ!%C1QO>H)A_.-L"*=FU%7;G6UJEMKV@/LE/"-^!4'?DP00/B_&=M
M?5TV0*QUZ$C(HM91GJD!M/9 6_2R%Z=2KY'3TRVI@/ZH1:J@/KIY O1 >_2]
M/:<B'RX^"IOS'*G6'/GMJ515&=AQ-;AW#9P (BH2:-=93K_ 25B'5"%^"%+M
MBE1KS; )KU_ZT<$3 EIPHG5'JO6?:/V3JM: I2@,RV[O'9TJF'9B-<TSK".J
MI4X>;_/3K9C_(QP6VKM<#EC@2C@$"^WQ^P$+7 G'<.7V[A.UC06X9M*?=PIC
M #/C-Z#5"'&RH/I(-!A?PGWH\O6ZSMR@N[(->U^KZM9N8 (*FD:!HZF @MZC
M0)=4TP0<]!X'FN38M>*@VYF@W;;.!F5MI]7S\TO3V7)>+C,O^_35;L-F]V:[
MW< )BD+D#?^:!UG/GFO6Y@=3SOP@15<C(=.*/[\D]H?V!M(UU9/QH (@P+4[
MDG44WE@H7&B.(]G%4P(L4+Z["P;X@:!,EPIW Z;XF=J5HVB *<!4<P$C0!6@
MZLSPDV(Y[: *LJS]>:<PCD!&,60$]*O<!7B5$PTAU\K1!*YL9Z\)!MF5OJ#
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M.:Q392+*X=^[G6/!SCFF>CB_$_?+(/*?R?^-T^GDM_\/4$L#!!0    ( *J
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MOQAIV#M[X*"U$'^4]"C#FW'%U$2X&&)[3 9,QHJ!G@/!C]82_&="3'/K6CY
MJVQ?RH/%F/=]D<[2#R,(;"W S.<3);KI/X[3%*Q.I%LTZ+BX)O+"G8ABZ7+?
MK$L+ZN993%NMZ[@VA@ Z]M*537,5FFJ+OS><ZI%]5-I4K]IK_G[D--8:L12H
M>K5CMU\B4)U'IZH1Y37U88.1H=Y5&I6T\X1[>)S6=28/S"[EH[E=UAO\W85C
M01W6GZ(.0=^%$1A].OVAE%8O3((XFO9"KV@1\?P,\TFQF$3A'<XS,X5-\#"$
MS^]Y5)++-Q(:>T^@L"\&"U+T%]%W0?G42T*/)R'U"MCF@_0%=.Z#=3,L<(BI
M7-MJM-MU9\<#/P(/W/*'<Y.J=TE]%!FB53GI'%J-PV:]W6X]RA';H8#G$T/E
MO+%'.I2%$0OCD8C8'Q!**D]2E$PI:'#%9%[G[N^$8QNV%4_RI%+I+J+^8YK?
M=QNX%1MX?GW#SL83/YR*B+:PJ+O815C=+]-**9QFMH8.$AXE2!W)83S.%]NM
M5.EV7MKF?B?3=>IYD5#*_.\3S&>G9JM=.;D,!-/9@!ZARMY'\F[GV.XX:3DG
M]>"?E]%M>)^%1$>83 X3@,5CE_R+^@;VV8GV^AM";MAE= 6AJJ3*P14CV4[E
MI =80^] \N^_9Z]Z#ZY"(++_?W*B<PGFV+,.<8'=<.J6W>YTUH\+7AP?K^A_
M&)I@*G82 4O*"?>9>!!N$H-Q@9_!$Q%JYTQNQ68"3S-DZA*/L4:YX"T[*Y@=
MBOS\MR/';A\K%@M?3$8AN$(!A3D'&+;Z"6X2XY'@L(F>>.$'(^4G1GNKJS,T
MZZ> ;$&!8>%&?>&4;W^-<I!/(?#Q%1*WF#*QG<I)L]D&'5FO?Y]#J+(RN-6G
M^B-1$#%-GXE)>R/A?J'+*GP"AANT*&9:^N$#ZPL_O&=R0(T?P-"S(^M7-I ^
M,JM4P+FQ"#SA8<6"DN/$CWD@P#?SITQ!]*<&4QII!H1]0%8'A:&>,G=VEL \
M$>/!-&T;A#XLCN/0F9"8(5#=U8^E_O(3ITZG>G386/? R=&#-G @TVE6.\W'
M3XF>G@^DFTK?:BE.@;%\]EL@4<.QSS>K5I24VXK5M<(_(QD#GV*F*0E,6D(M
M.J[],/3[')@N!M;/-$<#;6VGW6P>O_(XU5 )T,B1B4UR-4G7"8A3TSDTLAH7
M2WJPDF?/;K/>AVOF-.I5Z/AT*[X3X)T SP3X)J12?D#M,U@F!&)5Z6W^*-([
M(Q$;&QHMRJ[=Y. *Y<2W4(:7"6\3V(UZ[N1W)[^;D-^K2*#QQ3N 5*R-/F-T
M.1B@@[Z:'!_^*'(,I++<'*V^9H[MIF<Y>_W]U81:]]V)]4ZLOX-8GRN5B.@)
MPMW:"?<2X6X(J[GGKB;<IN\W9LZ>*061BR-T3D!$PBL0Q%R(8#9I.Y,C "*L
MD1(H3=YL@S)K.-6VLUZAYU*]V*BVFIM1C,!TC4;K%52 KI:;OL6W(_35#G?$
M7+R;_-K2[[<1IS3TS73<#_V];STT>7D(7IB:?=I"D:I2T"KW(PF_S%3/%I;1
M;>+(T2E$W5HG3VVG3[R?V>MVY42_OP"PA^Z7 _:?5&MOLPF/V!WWDPV7=&PU
M%8U,:9'*2'A4.3G]_/%B1Z<%;DL=''V):-Z!1)DMUA78'7VY\((KC__)/OHA
M.)C@+?C@+[#///HBXE=0([L)<C=6$6ZG7CEQZ.8,TT]L,'IC@WF)P#MXC]<;
M_U@D+)5LQ]:2O:/4!F3;<38@VUL0_9P''L: @O6GS*7#6(#M"S@E@DK=YTY*
MI6( (@20"/Z0#:/P/AYA*#G!TU,.LBH&L 3=0,0PTMRAK1^F4=/<H8V^?MW(
MHDGLWSZF(YSZX3Y6W.M@U.E;3LD495>YY^?"^!2'[U?963G<3WK[8&.)CR==
M>$TQ^4B(]#0>*^8\G*\?*SX'(S[K(QG? \:74V1Q/GA$:K$&J%0%R(4ZB1$(
M."E $/ @I-1(H@3U E1--08^/2EU3HDNXB-3TEK^%!>GQTE1602 &[1$XDXJ
M& =J@P<NRA1W7;RMB)WQA4B/1Y[2=1C>LKQ,8X]G>9F\3JBR9Y7J3,HVP31?
MJ?*9>UUK$NI-Z$;"YUB,N/2]+;-Z?3:$]U7H)_'R(1MYHFO==\7:V;MBHVCF
MM R%U8\$_V+Q ?@H7>[?\ZG"],]+?'SLZ"]07.7E<>>Q&&LS!PZVPZZ%2OR8
MZE8O04IU50K#JO8/F1CV0E +V%!=D7^/7H[*TW!XPC7W\;J4Q,9>E9,/81*!
M"OKOA-Y&T$@GOL_^5_ (PXPF.^-1@*\,LBLJ[KT&E<=!S6'/:Y@2R./+K)3L
M(@RLCZ>G5SG*?8;N"0S])KHM9[R_VGI<!D]X%.O;'F%IK?@*RP%I?./^@'.J
M$K 0'(P%[EN4[5L ]L2ELD'@^23@"3 V=(QF4A#.I #-%<X:CR(A&,&I10.!
M9-K(O1>N?D*R81-@ ![V*$X_LVBI9D4'&19;&%UE&&D,D OI'4YCR8IH@.L]
M2( QU0AQ1-]W)/LR9IU.U6;@JHLX_#9)?3D<=ZZ?+RGB7]AIJEH&.K@0DW*(
M-8 GK-^J-U7V402PD[X_!?/OB@GNP^G,G[C21?H^@+J'0KN?VZ2QD=KY*$8,
M$U]+^T?T0L:)/Z17UOO3^6@$62#S/F9W2_7N!JF>*%DQ0P?66]QX'N5&BU0W
M3? 9UA&T'<P:#1<CHP?@<94W:5;(-<7\@4%;>6_Q,!&!,LBII(]GB),P !8A
M5GYLA$K<$1(SZ^.&BGA;<=B W&J +:"%G6$-3]P)/YS0$>7>]<]\/#E^OU\$
M(QNHA(_%O0=LJ'>=6KD']IX\5KJ#D8ZLSNEN+>@$XV-; UXF[L@80?=D! XG
ML!9YSA$=WBT;AYOVZ+9JKEA@Z ^H='I<C=@'+'_>^]#[L']@C@A  ^#*B>$^
MV U TB6BNWPB8[I[ MB"^B$8!L"MN8UQ<=8!S'J@SR"(S\$$CE-61\<[\O!-
M=NVE(VY%,+FOPAFLF9W\10 M!3O'-)%0\0&[Y0^XP^\%H.P:6XE[<SH.HUC^
M2_^P=_;+^>W[T_U,XSZN8%WNNRB)&GF=K:(B\(B>.M/;?# KV*9IM1P@BR,\
MFK_F8.)YF,PTN.VTLX&(,UG2H_LQ\X%%(_ \&9F, F1 4XJ9L %970M8B%M#
M0V%>C?5K4=5Y[N@+7P)ID 0<4!U)K<(!QLQ;>DS43(BG,*8$6PC\/0%-C8H
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M,/FG;CX77^SDJ+1=K)L%(2^'7SNHSZZ:8G[:31AE^6K8ZMOFN916<,@CT4X
M$2("L2[/"0U.,LV$=2K_S_QY9$9&E@M"G?)$&"F(M9H2SD%2ZIF2>+F?M"RJ
MS\_[/YQM88++J]KAQQ=[IUUW]GPZO;BXV+]T3;E?-_,IHY1/5Z/WEL,OU\9?
M\&%T9HR9#M]^'=H6FP;BM-GTTU_OCOTI+"PIJK:SE;\Q@.9#]_47;ZO)I]=?
MXM"V>-X.O_^N]K8; 'UW"9-OCNA_(JMAI+]$,D9XMG_9AKV7SR:3:\_9QC=U
M"1\A3I8?__YXN*ZTJ+II*!;3Y9BI+4M4/,S079W!B[VV6)R5L+IVVD#\IOK5
MDGM1>2_GW_ULTV1-IRBD\><."%Z%JM_B(VK<-'NZYJ]SD0#1GI?=B(K7YQY5
M;[VPQ9@.7IMZ!+7#1&0!"P?-F%+OS'M+YTKD?87]E'8QAVK?UXOIH.V@QC!\
M9.>P"K'?UX<S5*2/JI11,0A9G^26&*1>5$4?2-[AC\N9>ML)LN"R@RK =019
M&2IK?V=0V<>O^JO#2^N@'*[. A2S-U57=%>'59\T[%(='':P:&?6.:. 9\3F
M3A$1A2'.&DI 12V%DU1JMHZL76V!%OS^O/XR12O(C8G^0^^O:U\];/O:<0DK
M*J ]L:Z$F91:9H8&8@%CKO!1$1-P.0PR%P('(55(7\3*W%W=-\A?-:L5+&^&
M'XKIL:D7HQ/KZC%<=@T$->]-ZB9 @U4,?C7<H,]]6;<07NQUS3G<7*RK#K?M
MFQ+Z[8QW%LQO[I24+?RN:#NLF]HWE_[45G-X=5FTLR \LUQZK&<T.L1+7(KB
MBD">"Y59)YCR(VSA3;9'W H/I-(-6V,[CO=W0[H_-VV-%,I+':^':/\H);-[
M67P[PG?LCDCUF\7&IML]G48]JBM_,ESC493WA&4B8AP+EFB6>^)H1@W-A'0N
M,6C_ JAW*K)?SO0'/#@B2T 5LT_O_SB>*?#12FV(S@UVC#X MIA*XSI ,YE%
M&7+]"(3]A-<,^T\W$+\:&I/=IOKT'K@$+]<I+EIG1+=E=-Z2N;5GL^/.=D,2
M/BAMVWZ(QUWM/P][4'FL%90%[/&#)D)G@6BI \F"$MS%W*.R!]A%V[K!P4M+
M2WYEUZZNW'#\KIC=3*/C^G@=/DN%?UO/<C,_1M$C,NHV]-?5_-H\.S*N^J?X
M>L0P_8 RP54T.LN(LBHG@FI)'.>"9%I1:5C(E,QVE/XW$O(OA_\C+OX9T.O%
MHJX&07\-J6[&:!:H]H$$82T1X#2Q-%*2@378-G(MC1V;^7T1ORZ/CT7F/N@D
MMXZ8W_MSJ=DKMD_I,51%W;RO.VA?GP,RD$ME3C+K<JPW7%]T")$;XOK]'7-A
MP.4L%_9>?;U^V/5],SN+=&0/CMTK#<W# 0:JQI:'58#+/^%J9KP35,1(C+<8
MHW(#Q#"7$\< =*9\Y/!0S?;8DXY[9G]Q]?V33KZ2G#GBG=L+>H49*/19Z&UI
MYS,EG;4,&PP5<7.)8#BQW#B2<<L=8.G)G4BB>L?<SM/<WGDCWZ/'X,\;7-VJ
M7WQO%X!E!&@K+'8.F@DB,LB(B107:3EC2L<<._XDF)NL[CS39%>.V#WU>HX:
MZ%,]5'XH%@_;]AR:D_XQ3/,A1DP-VM+@&<=^46O41K%SQ%RC"8L""T;@5FF3
MA/E["G8>^:@N7L?/1\1_6Q47P#6PG$"DC@@E!'&1,9++J*CPH&1XJ'7Z8?!/
M&/FV;EV'+9+">%T6ON@/:?_"WK I;#E3T8=@L?G+M8N85!1VA33C! ,2QAU)
M5<9H6A!?L[GS<!/=N XU3X'Z#V:3#JI^NYU7Q?6[/7V/[T!*+/F$,[$_=[>X
MRX"3G/)<T.BU8VF5UD:S.X\VW9GK=&5Z=W18^;HYJYM!SW"P<U"?8XU_=5 '
MF!F)I1\-D43#;?_2FR)68(#105M,'='J!\^X'O]BPP,B=I[\V(Y>WP<J91^L
M7I@YP;%XP<<L1D9D#K(_B:'$X;J(UA!L!@:_Y$G ;UO;>;);NVX=H1X#X1&F
MC#J\J<)KW%XS';6.')<1+*?]4S-<59"!,,\8BV SFJ4]&]YH]LE W=Z9ZW1-
M>J#^"/.B[1I;=4-?)P(U,F>6<"SMB+ 2RP+!!<&4(2((RIU[S%/C[T7FNU9W
MGFVR*S><?B0=8ET+>EN4\/Y\."ZUP03G,6PPH0S6\#HCVD>'FXU2GTOC!7WH
M"<-CN=Y8?"),MW3A!IXC'#F?V,O#@"&DB,M";ZG,!\B]X/UI:8[5GA&66(NI
M7D7,\<R)Z+,-K_;^,-QOF'\BI,=P[@;L24==U\I>A=! VR[_ZM>;S62D5(&1
MA$L?L'V+0+#"LX1REAG,*0I@#.0;3#\1W*E.W8 ZZ5CKCJH#_/BA.:DOJAEF
M"V7Z)LY!_PS3<$5<!E@OY%F(!L-.;L9HE=8,/RW,6SIT ^2DXZP[FH9F[4-S
MU-1?BLK#S%,-+J"2J)5&89YCC6\E,19B4(#]NQJ1]#WK3PMWBFLW,$\Z[;HC
M[*AN.UO^KS@;NO,8K)?]"L&ZC(B<.V*B"(3'P"Q57*J0=N3U;=M/B_?V;MU
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MIBOS<&%V$ANNS.VPWT>:G=1ZM=D]VE^<?U5%7:NYM>2[^>K'](L)E8(FG$
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M;F=S<F5L96$N:'1M4$L! A0#%     @ JH!$6LZEKQ8%&0  2:P  !$
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MR0  86UG;BTR,#(U,#(P-%]P<F4N>&UL4$L%!@     &  8 DP$  +#2
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>amgn-20250204_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:amgn="http://www.amgen.com/20250204"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:exch="http://xbrl.sec.gov/exch/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="amgn-20250204.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
        </entity>
        <period>
            <startDate>2025-02-04</startDate>
            <endDate>2025-02-04</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-04</startDate>
            <endDate>2025-02-04</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000318154</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">amgn:A2.00SeniorNotesDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNGS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-04</startDate>
            <endDate>2025-02-04</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-24">0000318154</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-25">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-02-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Amgen Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37702</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">95-3540776</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">One Amgen Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Thousand Oaks</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">91320-1799</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">805</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">447-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-17">Common stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-18">AMGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-20">2.000% Senior Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-21">AMGN26</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-26">2025-02-04</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-27">2025-02-04</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
